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ABSTRACT 
Several different disinfection by-products (DBPs) are formed during the chlorination 
of raw water. The DBPs which pose a cancer risk to man are not known. One 
candidate group is the chlorohydroxyfuranones (CHFs). Of the CHFs, 3-chloro-4-
(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), 3-chloro-4-(chloromethyl)-5-
hydroxy-2(5H)-furanone (CMCF), 3,4-dichloro-5-hydroxy-2(5H)-furanone (MCA), 
and 3-chloro-4-methyl-5-hydroxy-2(5H)-furanone (MCF) are all genotoxic in 
mammalian cells in vitro. MX is also carcinogenic in Wistar rats. 
This thesis focuses on the underlying cellular mechanisms involved in MX-induced 
carcinogenicity. Point mutations were analyzed in the p53 tumor suppressor gene 
(exons 4-7) and the Ki-, Ha-, and N-ras oncogenes (exons 1-2) of the liver tumors of 
the MX carcinogenicity study in rats. The expression of p53 protein was examined 
immunohistochemically in the liver and thyroid gland tumors. In addition, the 
expression of p21 Ki-ras protein was determined in several thyroid gland tumors. 
No mutations were detected in ras genes in 50 rat liver tumors. The mutation 
frequency of p53 gene was low (4 mutations). Moreover, the mutations had no 
consistent pattern, scattering to different codons and positions of the codon. 
Immunohistochemical analyses revealed that hepatocellular adenomas and 
carcinomas did not overexpress p53 protein. Instead, all the cholangiomas and 
cholangiocarcinomas, which originate from the bile duct epithelial cells, 
overexpressed p53 protein. The epithelial cells of the hyperplastic bile ducts of aged 
rats overexpressed p53 protein independently of the MX treatment. The MX-
induced thyroid tumors did not have an abnormal expression of p53 or p21 Ki-ras 
proteins. 
In other experiments, the effects of MX, CMCF, MCA, and MCF were investigated 
on gap junctional intercellular communication (GJIC), first in Balb/c 3T3 mouse 
fibroblast cells and then in WB-F344 rat liver epithelial cells, the target cells of MX 
tumorigenicity. Inhibition of GJIC is a common mechanism among tumor 
promoters. Concentration- and time-responses for inhibition of GJIC by CHFs were 
studied in both cell lines. In addition, the role of protein kinase C (PKC) and 
  
 
mitogen-activated protein kinase (MAPK) signaling pathways in the inhibition of 
GJIC by CHFs was defined in WB-F344 cells. The effects of CHFs on the gap 
junction structural protein, connexin43 (Cx43), and its mRNA levels were also 
determined. 
All the studied CHFs inhibited GJIC dose-dependently in both cell lines. The orders 
of potency to inhibit GJIC in Balb/c 3T3 and WB-F344 cells were 
MX>MCA>CMCF>MCF and MX>CMCF≈MCA>MCF, respectively. In Balb/c 
3T3 cells MX inhibited GJIC already at nanomolar concentrations. In WB-F344 
cells, the inhibition of GJIC by CHFs was reversible and was dependent upon the 
activation of the MAPK signaling pathway. CHFs decreased the expression of the 
Cx43 protein without altering its mRNA level. These results suggest that the main 
mechanism by which CHFs inhibit GJIC in the liver cells was to decrease the 
expression of Cx43. 
Altogether, the results suggest that point mutations in p53 and ras genes do not 
contribute to the MX-induced liver and thyroid tumorigenesis in rats. In contrast, 
inhibition of GJIC may be one mechanism by which MX can promote tumor 
development. 
 
Keywords: chlorinated drinking water, chlorohydroxyfuranones, MX, 
carcinogenesis, rat, ras, p53, gap junctional intercellular communication, GJIC, 
Balb/c 3T3, WB-F344 
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TIIVISTELMÄ 
Juomaveden kloorauksessa muodostuu useita erilaisia sivutuotteita. Ei kuitenkaan 
tiedetä, mitkä sivutuotteet aiheuttavat syöpäriskin. Yksi tällainen mahdollinen 
sivutuoteryhmä on kloorihydroksifuranonit, joista 3-kloori-4-(dikloorimetyyli)-5-
hydroksi-2(5H)-furanoni (MX), 3-kloori-4-(kloorimetyyli)-5-hydroksi-2(5H)-
furanoni (CMCF), 3,4-dikloori-5-hydroksi-2(5H)-furanoni (MCA) ja 3-kloori-4-
metyyli-5-hydroksi-2(5H)-furanoni (MCF) ovat genotoksisia nisäkässoluissa in 
vitro. MX aiheuttaa myös kasvaimia Wistar-rotissa. 
Tässä väitöskirjatutkimuksessa on selvitetty MX:n karsinogeenisuuden solutason 
mekanismeja. Rotilla tehdyn MX:n syöpäkokeen maksakasvaimista analysoitiin 
pistemutaatioita p53 tuumorisupressorigeenissä (eksonit 4-7) ja Ki-, Ha- ja N-ras 
onkogeeneissä (eksonit 1-2). p53-proteiinin ilmentymistä tutkittiin 
immunohistokemiallisesti maksa- ja kilpirauhaskasvaimista. Lisäksi määritettiin p21 
Ki-ras-proteiinin ilmentyminen useista kilpirauhaskasvaimista. 
50:ssä tutkitussa rotan maksakasvaimessa ei havaittu lainkaan mutaatioita ras-
geeneissä. Mutaatiofrekvenssi p53-geenissä oli alhainen (4 mutaatiota). Mutaatioilla 
ei ollut myöskään yhteneväisyyttä. Ne jakaantuivat eri kodoneihin ja eri paikkoihin 
kodoneissa. Immunohistokemialliset tutkimukset paljastivat, että hepatosellulaariset 
adenoomat ja karsinoomat eivät ilmentäneet p53-proteiinia poikkeavasti. Sen sijaan 
kaikki kolangioomat ja kolangiokarsinoomat, jotka ovat peräisin sappiteistä, 
ilmensivät p53-proteiinia. Vanhempien rottien sappiteiden epiteelisolut ilmensivät 
p53-proteiinia riippumatta MX-käsittelystä. MX:n aiheuttamissa 
kilpirauhaskasvaimissa ei esiintynyt poikkeavaa p53- tai p21 Ki-ras-proteiinin 
ilmentymistä. 
Tutkittiin myös MX:n, CMCF:n, MCA:n ja MCF:n vaikutuksia solujen väliseen 
kommunikointiin. Tutkimukset aloitettiin hiiren Balb/c 3T3 fibroblastisoluilla ja 
jatkettiin rotan WB-F344 maksaepiteelisoluilla, jotka ovat MX:n 
karsinogeenisuuden kohdesoluja. Solujen aukkoliitosten kautta tapahtuva solujen 
välisen kommunikaation esto on yleinen tuumoripromoottorien mekanismi. 
Molemmilla solulinjoilla määritettiin pitoisuus- ja aikavasteet 
  
 
kloorihydroksifuranonien aiheuttamalle solu-solu kommunikaation estymiselle. 
Lisäksi WB-F344-soluilla selvitettiin proteiinikinaasi C:n (PKC) ja mitogeenin 
aktivoimien proteiinikinaasien (MAPK) merkitystä kloorihydroksifuranonien tässä 
vaikutuksessa. Kloorihydroksifuranonien vaikutukset aukkoliitosten 
rakenneproteiiniin, konneksiini43:een (Cx43), ja sen mRNA:han määritettiin myös. 
Kaikki tutkitut kloorihydroksifuranonit estivät aukkoliitosten kautta tapahtuvaa 
solujen välistä kommunikointia annosvasteisesti molemmissa solulinjoissa; Balb/c 
3T3-soluissa järjestyksessä MX>MCA>CMCF>MCF ja WB-F344-soluissa 
MX>CMCF≈MCA>MCF. Balb/c 3T3-soluissa MX esti solu-solu kommunikaatiota 
jo nanomolaarisilla pitoisuuksilla. WB-F344-soluissa kloorihydroksifuranonien 
aiheuttama solu-solu kommunikaation estyminen oli palautuvaa ja riippui MAPK-
signaaliketjun aktivoitumisesta. Kloorihydroksifuranonit vähensivät Cx43:n 
ilmentymistä muuttamatta kuitenkaan sen mRNA-tasoa. Näiden tulosten mukaan 
Cx43:n ilmentymisen vähentäminen oli päämekanismi, jolla kloorihydroksifuranonit 
estävät solu-solu kommunikaatiota maksasoluissa.  
Yhteenvetona voidaan todeta, että MX:n aiheuttamat maksa- ja 
kilpirauhaskasvaimet rotissa eivät johdu pistemutaatioista p53- ja ras-geeneissä. Sitä 
vastoin solu-solu kommunikaation estyminen voi olla yksi mekanismi, jolla MX 
edistää kasvainten kehittymistä. 
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ABBREVIATIONS 
AP site Apurinic/apyrimidinic site 
BCIP 5-Bromo-4-chloro-3-indolyl phosphate 
BSA Bovine serum albumin 
CA Chromosome aberration 
CHF Chlorohydroxyfuranone 
CHO cells Chinese hamster ovary cells 
CMCF 3-Chloro-4-(chloromethyl)-5-hydroxy-2(5H)-furanone 
Cx Connexin protein (gap junction structural protein) 
DBP Disinfection by-product 
DHPN N-bis(2-hydroxypropyl)nitrosamine 
DNA Deoxyribonucleic acid 
EMX (E)-2-chloro-3-(dichloromethyl)-4-oxobutenoic acid 
GJIC Gap junctional intercellular communication 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
GSH Glutathione 
hprt gene Hypoxanthine phosphoribosyl transferase gene 
IARC International Agency for Research on Cancer of the World Health 
Organization (WHO) 
LUMO Lowest unoccupied molecular orbital 
MAPK Mitogen-activated protein kinase 
MC 3-Methylcholanthrene 
MCA 3,4-Dichloro-5-hydroxy-2(5H)-furanone 
MCF 3-Chloro-4-methyl-5-hydroxy-2(5H)-furanone 
MEK 1 Mitogen-activated protein kinase kinase (upstream activator kinase 
of the MAPK) 
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MN Micronuclei 
MNNG N-methyl-N’-nitro-N-nitrosoguanidine 
mRNA Messenger RNA 
MX 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone 
NBT Nitroblue tetrazolium 
PCR Polymerase chain reaction 
PKC Protein kinase C 
PVDF  Polyvinylidene difluoride 
ROS Reactive oxygen species 
RNA Ribonucleic acid 
RT-PCR Reverse transcription-polymerase chain reaction 
SCE Sister chromatid exchange 
SDS-PAGE Sodium dodecylsulphate – polyacrylamide gel electrophoresis 
SL/DT assay Scrape-loading dye transfer assay 
SSCP Single-strand conformation polymorphism 
TBDE test Trypan blue dye exclusion test 
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TGGE Temperature gradient gel electrophoresis 
TPA 12-O-tetradecanoylphorbol-13-acetate 
TSH Thyroid stimulating hormone 
UDS Unscheduled DNA synthesis 
z-MX Z-2-chloro-3-(dichloromethyl)-4-oxo-butenoic acid 
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1 INTRODUCTION 
The treatment of drinking water for safe use was one of the most significant 
achievements of the last century in public health. Chlorination of drinking water 
reduced the mortality rates associated with waterborne pathogens and chlorination is 
still the most common disinfection technique worldwide. It is easily applied, 
controlled, and monitored. Chlorine is a cheap and highly effective disinfectant 
against most known pathogens. However, chlorination suffers from some serious 
drawbacks. One major disadvantage is the formation of disinfection by-products 
(DBPs). DBPs are formed during the chlorination process in the waterworks when 
chlorine reacts with natural organic matter present in raw water. The actual levels of 
DBPs can vary depending on the amount of chlorine added and the quality of the 
raw water. Chlorinated water prepared from surface waters contains substantially 
higher levels of DBPs than chlorinated water from ground waters. This is because 
the content of organic matter is lower in ground waters (IARC, 1991). 
The detection of by-products in chlorinated drinking water has raised concern over 
the potential health risks of long-term exposure to DBPs. Chlorination may account 
for a substantial portion of the cancer risk associated with drinking water. Several 
epidemiological studies point to an association between the consumption of 
chlorinated drinking water and an increased risk of cancers of the bladder, rectum, 
pancreas, kidney, stomach, colon and lymphomas (Cantor et al., 1987; Morris et al., 
1992; 1995; Koivusalo et al., 1994; 1995; 1997; Doyle et al., 1997; Villanueva et 
al., 2004). Several hundreds of different by-products have been identified in the 
drinking water and there are likely to be more DBPs still to be identified. Many 
DBPs have mutagenic and carcinogenic properties, but the broad category of DBPs 
includes also compounds whose toxicological effects have not yet been evaluated 
(IARC, 1991; Richardson et al., 2002). 
The by-products or groups of by-products in chlorinated drinking water responsible 
for the cancer risk to man are not known. One candidate group is the 
chlorohydroxyfuranones (CHFs). Of the CHFs, 3-chloro-4-(dichloromethyl)-5-
hydroxy-2(5H)-furanone (MX) is known to be an extremely potent, direct acting 
mutagen in Salmonella typhimurium strain TA100 (Meier et al., 1987a) and a 
multisite carcinogen in Wistar rats (Komulainen et al., 1997). In the overall 
evaluation conducted by the International Agency for Research on Cancer (IARC) 
of the World Health Organization (WHO) MX was designated as a group 2B 
carcinogen (possibly carcinogenic to humans) (IARC, 2004).  
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In this thesis, the underlying cellular mechanisms of MX carcinogenicity in rats 
were elucidated to obtain further information for assessment of its role in the cancer 
risk. The effects of three other CHFs were evaluated on tumor promoting properties 
to elucidate also their possible role in the cancer risk. The MX-induced tumors in 
rats were the starting material for the present work. Mutations in ras and p53 genes 
were believed to be important candidates in tumor development. The work was 
expanded to tumor promotion studies, due to observation that MX promoted the 
development of the transformation foci in the two-stage mouse fibroblast cell 
transformation assay in vitro (Laaksonen et al., 2001). 
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2 REVIEW OF THE LITERATURE 
2.1 The process of chemical carcinogenesis 
Cancer usually develops slowly, with a latent period between the initial exposure to 
a chemical carcinogen and the ultimate development of malignant neoplasia. As 
normal cells progress to the neoplastic stage, multiple genetic and epigenetic 
changes occur. The general multistage concept of chemical carcinogenesis consists 
of three individual stages: initiation, promotion and progression stages (Barrett, 
1993; Pitot, 1993) (Fig. 1). This may be oversimplification, carcinogenesis is a very 
complex process involving an array of effects and mechanisms (Bertram, 2001). 
Many carcinogens have both genetic and epigenetic properties and their primary 
mechanism of action can vary depending on the target tissue. Thus even the three-
stage model of initiation, promotion and progression cannot describe the  
carcinogenic process adequately (Barrett, 1993). 
2.1.1 Initiation 
Initiation is the process in which genotoxic agents evoke irreversible changes in the 
DNA resulting in altered cells with a clonal expansion advantage. Often the 
initiators are chemically-reactive xenobiotics, which are metabolized to activated 
forms which in turn produce carcinogen-DNA adducts. If these DNA adducts can 
evade the cellular repair mechanisms and persist, this may lead to miscoding, 
resulting in permanent mutations. In the carcinogenesis process, two classes of 
genes are the critical targets of genotoxic agents. Genes which are activated by a 
point mutation are called oncogenes (e.g. ras) and genes which are inactivated by a 
point mutation are called tumor suppressor genes (e.g. p53) (Bertram, 2001). Each 
cell contains two alternate forms of each gene, alleles. Activation of a single allele 
of an oncogene is sufficient to induce some aspects of the neoplastic phenotype even 
though there may be the simultaneous expression of the other normal allele. Because 
in most cases the normal tumor suppressor allele can function in the presence of the 
damaged allele, both copies must be inactivated before loss of function is 
manifested. Genotoxic agents can influence the activation of oncogenes by inducing 
point mutations, chromosome rearrangements and gene amplification. Loss of 
function of tumor suppressor genes can be a consequence of point mutations, 
deletions and chromosome loss (Diamandis, 1997; Bertram, 2001). 
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Figure 1. The general multistage model of chemical carcinogenesis (modified from 
Klaunig et al., 2000). Initiation: Initiating agents cause irreversible mutations in the 
genome. Promotion: Promoting agents cause the expansion of initiated cell clones. 
Progression: Preneoplastic cells progress into a malignant cell population. 
 
2 . 1 . 1 . 1  p 5 3  t u m o r  s u p p r e s s o r  g e n e  
The p53 tumor suppressor gene is mutated in the majority of human cancers 
(Hainaut and Hollstein, 2000), but clearly less frequently in tumors induced in 
animals (Stanley, 1995; Perantoni and Rice, 1999). The timing when mutations in 
the p53 gene occur during cancer development is variable from one cancer to 
PROMOTION 
(nongenotoxic 
effects) 
INITIATION 
(genotoxic 
effects) 
PROGRESSION 
Irreversible inherited genetic alterations: 
- point mutations in proto-oncogenes 
(activation) and tumor suppressor 
genes (inactivation) 
- chromosomal mutations e.g. 
activating proto-oncogenes 
by initiating agents or “spontaneous” 
mutagenesis (free radicals from metabolism or 
inflammation) 
Effects on: 
- cell proliferation 
- GJIC 
- apoptosis 
- oxidative stress 
- gene expression 
by promoting agents 
Effects: 
- increased genetic instability (due to 
mutations e.g. in cell cycle 
checkpoint genes, DNA repair genes 
and segregation genes) 
- structural and numerical changes in 
chromosomes 
- oncogene amplification 
by inducing genotoxic agent or by selection 
Initiated cell 
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another. p53 mutations seem to occur at an early stage in many types of cancer, 
which are directly caused by exogenous carcinogens (Guimaraes and Hainaut, 
2002). The p53 gene encodes for p53 protein that participates in many cellular 
functions: cell cycle control, DNA repair and programmed cell death (apoptosis). 
The p53 protein is a sensor of multiple forms of genotoxic (e.g. radiation, 
carcinogen) and non-genotoxic stress (e.g. hypoxia) (Pluquet and Hainaut, 2001). In 
response to cellular stress, p53 protein can induce cell cycle arrest which allows the 
cells to repair DNA damage before further rounds of replication. If the DNA damage 
is excessive, p53 can induce apoptotic cell death. Thus, p53 can prevent the growth 
and impair the survival of potentially malignant cells. If the point mutations in the 
p53 gene induce the inactivation of the p53 protein function, then the cell cycle 
progresses into replication despite the presence of DNA damage (Ryan et al., 2001). 
 
2 . 1 . 1 . 2  R a s  o n c o g e n e s  
Ras oncogenes (Ki-, Ha-, and N-ras) are frequently mutated in human cancers and 
rodent tumors (Bos, 1989; Stanley, 1995; Sills et al., 1999; Barletta et al., 2004). 
Ras genes encode for 21-kDa proteins (p21ras) which are associated with the inner 
face of the plasma membrane and have guanosine triphosphate/guanosine 
diphosphate (GTP/GDP) binding activity (Barbacid, 1987). Most ras molecules in 
the cell exist in their inactive GDP-bound state. In normal cells, the hydrolysis of 
GTP to GDP returns the active ras protein to the inactive state. The ras mutations 
found in tumors lock the ras protein in a constitutively active GTP-bound state 
(Singh et al., 2005). Ras proteins are activated in response to a wide variety of 
extracellular stimuli (e.g. chemical agents, growth factors, cytokines, adhesion 
signals) and regulate downstream signaling pathways (e.g. ras/raf/MEK/MAPK). 
The mutated forms of ras protein are known to stimulate proliferation, 
transformation and cell differentiation. In physiological conditions, ras proteins 
function as intracellular switches in the signaling pathways that control multiple 
biological processes including cell cycle progression and apoptosis (Macaluso et al., 
2002; Rodriguez-Viciana et al., 2004). 
2.1.2 Promotion 
Promotion is the stage when the clonal proliferation of initiated cells occurs in the 
cancer process (Fig. 1). In this stage, the promoting agents modulate cell growth and 
cell death without inducing mutations. In contrast to the initiators, the effect of 
promoters is reversible and exhibits a threshold. The exact mechanisms by which 
promoters cause their effects have not been established, but several mechanisms 
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may be involved in nongenotoxic chemical carcinogenesis e.g. induction of cell 
proliferation in the target tissue, inhibition of cell-to-cell communication, blockade 
of apoptosis, production of reactive oxygen species (ROS), and modification of gene 
expression (Klaunig et al., 2000). 
 
2 . 1 . 2 . 1  G a p  j u n c t i o n a l  i n t e r c e l l u l a r  c o m m u n i c a t i o n  
( G J I C )  
The reversible inhibition of GJIC has been demonstrated to be a common effect of 
many chemical tumor promoters (Trosko and Chang, 1988). Gap junctions, 
composed of connexin (Cx) proteins, are membrane-associated channels, which 
permit the direct intercellular exchange of low molecular weight (<1-2 kDa) 
molecules (e.g. sodium, potassium, calcium, cAMP, ATP, inositol triphosphate) 
between the cytoplasms of adjacent cells (Lawrence et al., 1978; Pitts and Finbow, 
1986; Saez et al., 1989). This has a major physiological role of intercellular 
communication to maintain homeostatic control of growth, development, 
differentiation, apoptosis, and adaptive responses of differentiated cells in solid 
tissues (Trosko and Ruch, 1998). Extra-cellular signals, such as tumor promoting 
chemicals, can induce changes in gap junction function by causing transcriptional, 
translational or post-translational modifications of the Cxs (Trosko and Ruch, 1998; 
Chipman et al., 2003). Therefore, disruption of GJIC results in malfunction in cell 
growth and loss of homeostatic control and could ultimately be a cause of promotion 
of tumors (Trosko et al., 1998). 
2.1.3 Progression 
In the progression of carcinogenesis, the initiated cells progress into forming a 
malignant cell population (Fig. 1). The stage of progression is characterized by 
increasing aggressiveness of the tumor. The major hallmark of the stage of 
progression is evolving genetic instability. This is manifested both at the single 
nucleotide level, resulting in accumulation of multiple point mutations, or at the 
chromosomal level where it is reflected in translocations, deletions, amplifications 
and whole chromosome aneuploidy (Loeb and Loeb, 2000; Pitot, 2001). 
The findings of MX and three other CHFs [3-chloro-4-(chloromethyl)-5-hydroxy-
2(5H)-furanone (CMCF), 3,4-dichloro-5-hydroxy-2(5H)-furanone (MCA), and 3-
chloro-4-methyl-5-hydroxy-2(5H)-furanone (MCF)] that are likely to contribute to 
the chemical carcinogenesis are discussed in the following paragraphs. 
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2.2 Occurrence of chlorohydroxyfuranones (CHFs) 
CHFs are formed during disinfection treatment of drinking water as by-products 
from the reactions of chlorine with humic acid materials present in surface waters 
(Hemming et al., 1986; Kronberg and Franzén, 1993). MX has been detected in 
chlorinated drinking water all around the world e.g. in Australia, Canada, China, 
Finland, Japan, the Netherlands, Russia, Spain, the United Kingdom, and the United 
States (Kronberg and Vartiainen, 1988; Kronberg et al., 1988; Backlund et al., 
1989b; Andrews et al., 1990; Fawell and Horth, 1990; Suzuki and Nakanishi, 1990; 
Kinae et al., 1992; Zou et al., 1995; Romero et al., 1997; Simpson and Hayes, 1998; 
US EPA, 2002; Wright et al., 2002; Egorov et al., 2003). Its concentration in tap 
water has varied from non-detectable levels up to 310 ng/l. The concentration of MX 
in chlorinated drinking water depends on the disinfection conditions. Formation of 
MX is favoured under acidic conditions and high chlorine doses (Backlund et al., 
1989a). 
With respect to the other CHFs, the concentrations of CMCF, MCA, and MCF in 
chlorine-disinfected drinking waters in Finland do not differ notably from that of 
MX (Kronberg and Franzén, 1993; Smeds et al., 1997). However, MX dominates as 
a contributor of the overall mutagenicity measured in S. typhimurium strain TA100. 
According to Kronberg and Franzén (1993) MX accounted for 43% but CMCF a 
mere 3%, of the total mutagenicity of chlorinated drinking water in the Ames test 
(strain TA100). The activity contribution of MCA and MCF was negligible. In 
another study, MX was observed to account on average for 31% (from 7 to 67%) of 
the total mutagenicity of the Finnish chlorinated drinking water extracts, while the 
total contribution of CMCF, MCA, and MCF was on average only 4% (Smeds et al., 
1997). It should, however, be noted that S. typhimurium TA100 is exceptionally 
sensitive to the mutagenicity of MX, this being in some way related to the properties 
of the strain and the structure activity characteristics of the compound. 
2.3 Chemical properties of  chlorohydroxyfuranones (CHFs) 
The chemical structures of MX, CMCF, MCA, and MCF are presented in Figure 2. 
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O
OHO
R Cl
MX:      R = CHCl 2
CMCF:  R = CH 2Cl
MCA:    R = Cl
MCF:     R = CH 3
 
 
Figure 2. The chemical structures of the studied CHFs. 
 
MX undergoes a pH-dependent tautomerism. In acidic solutions, MX is a furanone 
but at physiological pH it is predominantly in the open-ring form (z-MX) (Meier et 
al., 1987b; Holmbom et al., 1989) (Fig. 3). However, the closed-ring form may be 
required for the cell membrane penetration and it may be a more active mutagen. 
The mutagenicity of MX in S. typhimurium strain TA100 has been noted to be about 
3.3-fold higher at pH 6 compared to pH 8 (Meier et al., 1987a). At pH 5-9, the 
isomerization to the geometric isomer of the open-ring form (EMX) takes place 
(Holmbom et al., 1989). The EMX appears to have less than one-tenth of the 
mutagenic activity of MX (Kronberg et al., 1988).  
                       MX                                       z-MX (open-ring form)                      EMX (geometric isomer)            
 
Figure 3. Tautomeric forms of MX. z-MX, Z-2-chloro-3-(dichloromethyl)-4-oxo-
butenoic acid; EMX, (E)-2-chloro-3-(dichloromethyl)-4-oxobutenoic acid. 
 
MX is a polar, water soluble compound. pH has only a minor effect on the solubility 
of MX, but a major effect on its stability in water (Vartiainen et al., 1991). MX has a 
low bioaccumulation property. The n-octanol/water distribution coefficient logPow at 
the pH 2 is about 1 (Holmbom et al., 1984; Vartiainen et al., 1991) whereas at pH 9 
it is about –1 (Vartiainen et al., 1991). 
Compared to MX, there is less data on the chemical properties of CMCF, MCA, and 
MCF. MCA has, like MX, the pH-dependent tautomerism. The furanone ring opens 
above pH 7. MCA is also more active in its closed form. The mutagenic activity at 
O O
Cl
Cl
Cl
HO
H
O
Cl
Cl
Cl
H HO
H
OHCl
O Cl
Cl O
O
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pH 6 is about 10 times that observed at pH 8 (Meier et al., 1986). The chemical half-
life values (ct1/2) for MX and CMCF, indicating stability under S. typhimurium 
mutagenicity assay conditions (about at pH 7), has been 11 and 44 hours, 
respectively (LaLonde et al., 1991b). 
2.4 Genotoxicity of chlorohydroxyfuranones (CHFs) 
2.4.1 Genotoxicity in vitro 
2 . 4 . 1 . 1  M X  
MX is genotoxic in various bacterial strains (IARC, 1991; McDonald and 
Komulainen, 2005). MX is a direct-acting mutagen, in fact the addition of a 
metabolic activator (S9 fraction of rat liver or human placental homogenate) 
decreases the bacterial mutagenicity of MX (Ishiguro et al., 1987; Meier et al., 
1987a; Vartiainen et al., 1989; Tikkanen and Kronberg, 1990; Cozzie et al., 1993). 
MX is one of the most potent compounds ever tested in S. typhimurium strain 
TA100 (up to 13 000 revertants/nmol) (Meier et al., 1987a), S. typhimurium strain 
TM677 and the Escherichia coli prophage-induction assay (DeMarini et al., 1995). 
MX has high affinity for protein and other cellular nucleophiles, which decreases the 
mutagenic response of MX in bacteria. This kind of a decrease has been observed 
with bovine serum albumin (BSA), glutathione (GSH), SO2, S2O32-, pyrrolidine, 
cysteine, cysteamine, dithiothreitol, and 2-mercaptoethanol (Ishiguro et al., 1987; 
Haataja et al., 1991; Cozzie et al., 1993; Watanabe et al., 1994). 
MX is genotoxic also in mammalian cells; MX-induced DNA lesions, unscheduled 
DNA synthesis (UDS), gene mutations, sister chromatid exchanges (SCEs), 
chromosome aberrations (CAs) and micronuclei (MN) have been detected in a 
number of rat, mouse, hamster and human cell lines (Table 1).  
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Table 1. MX genotoxicity in mammalian cells in vitro. 
_________________________________________________________________________________________ 
Endpoint/cell line References (in alphabetical order) 
_________________________________________________________________________________________ 
 
DNA damage (alkaline elution, alkaline Brunborg et al., 1991; 
DNA unwinding assay, comet assay, Chang et al., 1991; 
unscheduled DNA synthesis)  Holme et al., 1999; 
 Le Curieux et al., 1999; 
 Chinese hamster ovary (CHO) cells (+)a Marsteinstredet et al., 1997a; 
 Chinese hamster V79 cells (+) Mäki-Paakkanen et al., 2001; 
 Mouse primary hepatocytes (+) Nunn and Chipman, 1994; 
 Rat primary hepatocytes (+) Nunn et al., 1997 
 Rat primary testicular cells (+) 
 Rat testicular germ cells (+) 
 Human lymphoblastoid cell line (CCRF-CEM) (+) 
 Human peripheral blood mononuclear cells (PBMC) (+) 
 Human proximal tubular epithelial cells (LLC-PK1) (+) 
 Human white blood cells (+) 
 Promyelocytic human leukaemia cell line (HL-60) (+)  
-------------------------------------------------------------------------------------------------------------------------------------- 
Mutation (induction of TGr or OuaR mutants, Harrington-Brock et al., 1995; 
or mutations at the thymidine kinase locus) Hyttinen et al., 1996; 
  Jansson and Hyttinen, 1994; 
 CHO cells (+) Matsumura et al., 1994; 
 Chinese hamster V79 cells (+,−)b Mäki-Paakkanen et al., 1994; 
 L5178Y mouse lymphoma cells (+) Woodruff et al., 2001 
 Human B-lymphoblastoid cell lines (+) 
-------------------------------------------------------------------------------------------------------------------------------------- 
SCEs Brunborg et al., 1991; 
  Jansson et al., 1993; 
 CHO cells (+) Mäki-Paakkanen et al., 1994; 2001 
 Chinese hamster V79 cells (+) 
 Rat peripheral lymphocytes (+) 
-------------------------------------------------------------------------------------------------------------------------------------- 
CAs Harrington-Brock et al., 1995; 
  Jansson et al., 1993; 
 CHO cells (+) Meier et al., 1987a; 
 L5178Y mouse lymphoma cells (+) Mäki-Paakkanen et al., 1994; 2001 
 Rat peripheral lymphocytes (+)  
-------------------------------------------------------------------------------------------------------------------------------------- 
MN Le Curieux et al., 1999 
 
 L5178Y mouse lymphoma cells (+) 
_________________________________________________________________________________________ 
aPositive result. 
bPositive, when MX was diluted in a buffered salt solution, but negative when MX was diluted in tissue culture 
medium (Matsumura et al., 1994). 
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In mammalian cells, the capability of GSH to reduce the mutagenic activity of MX 
does not seem to be so straightforward as in bacteria. In rat testicular cells, cellular 
GSH had only a minor effect on the MX-induced DNA damage (Brunborg et al., 
1991). In primary rat hepatocytes, MX did not produce detectable DNA strand 
breaks at similarly low concentrations as the mutagenicity in bacterial cells, which 
may indicate that there are more efficient protective mechanisms and structures in 
general in mammalian cells than in bacteria. Depletion of GSH did not enhance 
induction of DNA damage by MX in primary rat hepatocytes (Chang et al., 1991). 
MX can bind to purified DNA. MX induces single-strand DNA breaks and 
apurinic/apyrimidinic (AP) sites in bacteriophage PM2 and plasmid ΦX174 DNA 
(Hyttinen and Jansson, 1995; LaLonde and Ramdayal, 1997). The presence of GSH 
increases the cleavage of ΦX174 by MX (LaLonde and Ramdayal, 1997), although 
GSH decreases the bacterial mutagenicity of MX (Ishiguro et al., 1987). According 
to the authors, that might be explained by the presence of GSH – MX reaction 
products that may be less potent bacterial mutagens, but better cleavage agents than 
MX (LaLonde and Ramdayal, 1997). 
 
2 . 4 . 1 . 2  C M C F ,  M C A ,  M C F  
CMCF, MCA, and MCF, like MX, are direct-acting genotoxic compounds, but in 
bacteria they are less potent mutagens than MX. In general, the order of the potency 
of the four CHFs to induce his revertants in S. typhimurium strain TA100 is 
MX>CMCF>MCA>MCF (Ishiguro et al., 1988; LaLonde et al., 1991a; Kronberg 
and Franzén, 1993; Hyttinen et al., 1995; Knasmüller et al., 1996; Franzén et al., 
1998a; Mäki-Paakkanen et al., 2004). Also in two E. coli K-12 strains that differ in 
their repair capacities [uvrB/recA (repair-deficient) vs. uvr+/rec+ (repair-
proficient)] the order of the genotoxic potency is MX>CMCF>MCA (Fekadu et al., 
1994). In E. coli strains, MX is approximately 5-fold more effective a genotoxin 
than CMCF and ten times more potent than MCA. 
CMCF, MCA, and MCF induce DNA strand breaks, mutations, SCEs, and CAs in 
Chinese hamster ovary (CHO) cells (Jansson et al., 1995; Niittykoski et al., 1995; 
Mäki-Paakkanen et al., 2001) and MN in L5178Y mouse lymphoma cells and UDS 
in primary hepatocytes of Fischer F344 rats (Le Curieux et al., 1999). The order of 
the genotoxic potency of the CHFs differed in the various mammalian cell assays. In 
general, MCF has been the weakest genotoxin in the assays (2 – 200-fold weaker 
than MX). In the alkaline single cell gel, micronucleus, and UDS assay the 
genotoxic potencies of CMCF and MCA were comparable to or even higher than 
that of MX (Le Curieux et al., 1999). 
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In plasmid ΦX174, MCA evokes DNA strand cleavage at a higher rate than MX. In 
contrast to the situation with MX, the presence of GSH reduces the DNA cleavage 
action of MCA (LaLonde and Ramdayal, 1997). 
2.4.2 Genotoxicity in vivo 
2 . 4 . 2 . 1  M X  
MX has genotoxic potential also in vivo, inducing DNA damage in a wide range of 
tissues of rats and mice (Table 2a). Increases in nuclear anomalies, including MN, 
have been observed in the duodenum of B6C3F1 mice after a single oral dose of 
MX (Daniel et al., 1991) and MN are apparent in peripheral blood lymphocytes of 
Han/Wistar rats after oral administration of MX on three consecutive days (Mäki-
Paakkanen and Jansson, 1995). Increases in SCEs have been observed in peripheral 
blood lymphocytes and kidney cells of Han/Wistar rats after administration to MX 
by gavage on three consecutive days, and in peripheral lymphocytes of rats exposed 
to MX by gavage for 14-18 weeks (Jansson et al., 1993; Mäki-Paakkanen and 
Jansson, 1995). Other types of DNA damage (DNA single-strand breaks, alkali-
labile sites, differential DNA repair) have been detected in a variety of tissues both 
in rats and mice after a single dose of MX (Furihata et al., 1992; Fekadu et al., 1994; 
Sasaki et al., 1997). 
MX-induced DNA damage has not been observed in all studies (Table 2b). MX does 
not appear to affect the bone marrow of rats and mice (Meier et al., 1987a; Tikkanen 
and Kronberg, 1990; Brunborg et al., 1991; Meier et al., 1996; Sasaki et al., 1997; 
Jansson, 1998). These observations have raised doubts about the genotoxicity of MX 
in vivo. First, MX is extremely potent only in bacteria. Second, in general it may be 
difficult to demonstrate genotoxicity in vivo due to the presence of several efficient 
prevention and correction mechanisms. For example, tissues seem to have different 
capacities to repair MX-induced DNA damage. Sasaki et al. (1997) found that a 
single oral dose of MX could induce DNA damage in mice, which persisted between 
6-24 h in several tissues, though in liver, the effect reverted to background levels by 
three hours after administration. Therefore, timing in respect to dosing may be 
important for observation of the damage. The other reasons may be 
pharmacokinetics (distribution to tissues) and different cellular defence systems in 
addition to correction of DNA damage. Further evidence for in vivo genotoxicity of 
MX comes from studies with DNA-repair inhibition. Only mice pretreated with 
DNA repair inhibitors prior to MX administration, exhibited DNA damage in the 
liver, kidney, spleen, and colon (Holme et al., 1999). 
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2 . 4 . 2 . 2  C M C F  a n d  M C A  
Much less is known about the in vivo genotoxicity of other CHFs and the data do not 
allow any final conclusions to be drawn on this point. Nuclear anomalies have been 
detected in the duodenal, but not in the forestomach or proximal colon of B6C3F1 
mice after administration of a single oral dose of 0.47 mmol/kg MCA (Daniel et al., 
1991). In the animal-mediated bacterial differential DNA repair assay (two E. coli 
K-12 strains as indicators of DNA damage in male Swiss Albino mice), CMCF and 
MCA have been observed to cause genotoxic effects in the bacteria isolated from 
several organs (stomach, lung, intestine, liver, kidney, spleen) after a single oral 
dose of 200 mg/kg CHF. That study indicated that the genotoxicity distributed to 
tissues but it was not measured in the host cells. Compared to MX, the order of the 
genotoxic potency in the test was MX>CMCF>MCA (Fekadu et al., 1994). 
2.5 Carcinogenicity of MX 
The carcinogenicity of MX has been evaluated in one full-range study in rats and in 
a few shorter studies. MX was carcinogenic, inducing malignant and benign tumors 
in male and female Wistar rats when it was administered via the drinking water for 
104 weeks (Komulainen et al., 1997). Tumors occurred at the average daily doses 
which were not overtly toxic to rats (0.4, 1.3, 5.0 mg/kg for males and 0.6, 1.9, 6.6 
mg/kg for females). MX was a multisite carcinogen. The main target organs of the 
tumorigenicity were the thyroid glands and the liver. 
The thyroid glands were the main target organ in both male and female rats. Fifty-
five percent of the high-dose group males and 44% of the high-dose group females 
suffered follicular carcinoma. The frequencies of follicular adenoma in the high-
dose male and female group were 43 and 72%, respectively. Cholangioma, an 
epithelial tumor of bile duct, was the most prevalent MX-induced liver tumor: 66% 
of the high-dose group females exhibited cholangioma. The liver tumor incidences 
were clearly different between males and females. In the high-dose male group, the 
frequency of cholangioma was only 8%. 
In other tissues, MX increased in a statistically significant manner the tumor 
frequencies in adrenal glands (cortical adenoma in males and females), in pancreas 
(Langerhans’ cell adenoma in males), in mammary glands (adenocarcinoma and 
fibroadenoma in females) and in the lungs (alveolar and bronchiolar adenomas in 
males). In female rats, the tumor frequency of lymphomas and leukemias increased 
in a dose-dependent fashion. In the skin of male rats, the frequency of basal cell 
tumors increased statistically significantly, but according to the authors, this might 
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be a chance effect, because no such effect was observed in females or for other skin 
tumors. 
The study has been repeated in Wistar females at the dose of 1.7 mg/kg as a part of 
the CEMFEC-study (cocarcinogenesis of radiofrequency radiation) with essentially 
similar tumor spectra and results being obtained (Heikkinen et al., manuscript). 
MX increased the number of renal tumors in Tsc2 (the tuberous sclerosis complex 
tumor-suppressor gene) mutant Long-Evans (Eker) rats, which have a genetic 
susceptibility to suffer renal cancer (Hooth et al., 2002). MX was administered to 
rats in their drinking water at average daily doses of 0.28 or 4.2 mg/kg for males and 
0.45 or 7.2 mg/kg for females for 4 or 10 months. After 10 months, statistically 
significant increases in the number of renal adenomas were observed in the high 
dose male and female groups compared to control animals. 
Some other experiments have been performed to evaluate the carcinogenicity of MX 
(Nishikawa et al., 1994; 1999), but they were possibly too brief in duration to reveal 
carcinogenicity. Nishikawa et al. (1999) observed that after administration of 57 
weeks to MX in drinking water, there was indication of initial signs of 
carcinogenesis in thyroid glands and bile ducts. The same study demonstrated that 
MX may promote tumor development. 
The carcinogenicity of MX in mice has not been evaluated in a full-range study in 
conventional animals. MX did not evoke carcinogenicity in the groups of 10 male 
and female gpt delta C57BL/6J transgenic mice, when MX was given via the 
drinking water at the dose of 100 ppm for 78 weeks (Nishikawa et al., 2005) 
covering a similar concentration range of MX in drinking water as used in the rat 
study (between 5.9 – 70.0 ppm, Komulainen et al., 1997). It is uncertain how 
comparable such a strain is to conventional animals. The group sizes were also 
small, which may decrease the power to detect carcinogenicity. In mice, no tumors 
were found in distinct contrast to the situation in rats. 
In male and female C57BL/6J-Min/+ mice, which are highly susceptible to the 
spontaneous formation of intestine tumors, MX did not increase statistically 
significantly the number of tumors in small intestine, colon, or caecum compared to 
controls (Steffensen et al., 1999). MX was given via the drinking water at average 
daily doses of 33 and 42 mg/kg for males and females, respectively, for 6 weeks and 
then the mice received sterile water for 4 additional weeks before the termination of 
the experiment. The study was short but the strain was anticipated to be sensitive to 
develop tumors. 
The carcinogenicity of CMCF, MCA, and MCF has not been studied in any life-time 
bioassays. 
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In the short-term intestinal carcinogenesis assay, MCA increased the incidence and 
the number of aberrant crypt foci in the colons of Balb/cA male mice compared to 
untreated mice (Steffensen et al., 1999). MCA was given intrarectally at doses of 5 
or 10 mg/kg three times per week for four weeks. Prior to the termination of the 
experiment, mice received regular tap water for twelve additional weeks. Aberrant 
foci have been considered as an early sign of carcinogenesis. The brief duration of 
the study and the relatively small number of animals do not allow firm conclusions 
to be drawn with respect to carcinogenicity. 
2.6 Mechanisms of action of MX 
Though MX has clearly exhibited mutagenic and genotoxic properties in in vitro 
experiments, the primary mechanism of mutagenesis still remains to be clarified. 
MX has several effects which could contribute to mutagenesis and genotoxicity. It is 
the combination of these properties which ultimately may account for the 
mutagenicity of MX. 
2.6.1 Adduct formation 
It is generally accepted that the formation of DNA adducts is one key element in 
chemical carcinogenesis (Poirier, 2004). DNA adducts are formed in vitro in the 
reactions of MX with adenosine, guanosine, and calf thymus DNA (Le Curieux et 
al., 1997; Franzén et al., 1998b; Munter et al., 1998; 1999a). The adducts can be 
characterized by UV absorbance, nuclear magnetic resonance spectroscopy and 
mass spectrometry. Incubation of 2’-deoxyadenosine with MX at pH 7.4 at 37 °C for 
eight days resulted in the formation of three different adducts: M1A-dR (Le Curieux 
et al., 1997), pfA-dR, and Cl-pfA-dR (Munter et al., 1998) (Fig. 4). The yields of 
M1A-dR, pfA-dR, and Cl-pfA-dR were 0.01%, 0.03%, and 0.03%, respectively. The 
adducts M1A-dR and pfA-dR were formed also in the reaction of MX with calf 
thymus DNA at pH 6.5 (M1A-dR) or 7.4 (pfA-dR) at 37 °C for 4 days (Le Curieux 
et al., 1997; Munter et al., 1998). The yields of M1A-dR and pfA-dR were 1 and 0.6 
adducts/105 nucleotides, respectively. The adenine adducts M1A-dR and pfA-dR 
could represent premutagenic lesions. AT→TA transversions have been detected in 
S. typhimurium strain TP2428 induced by MX (Knasmüller et al., 1996). 
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                    M1A-dR                                      pfA-dR                                        Cl-pfA-dR 
                                      
                                                fBQ-pG                                        εfGuo-dR     
 
M1A-dR: 3-(2’-deoxyribofuranosyl-N6-adenosinyl)propenal 
pfA-dR: 3-(2’-deoxy-β-D-ribofuranosyl)-7H-8-formyl[2,1-i]pyrimidopurine 
Cl-pfA-dR: 3-(2’-deoxy-β-D-ribofuranosyl)-7H-8-formyl-9-chloro[2,1-i]pyrimidopurine 
εfGuo-dR: 3-(β-D-ribofuranosyl)-7-formylimidazo[1,2-a]purin-9(4H)-one 
fBQ-pG: 10-formyl-1,N2-benzoquinoline propenoguanosine 
 
Figure 4. Structures of the MX-DNA adducts. 
 
In the reaction of MX with guanosine, the formation of two adducts has been 
detected: εfGuo (at pH 9, 8.2, 7.4, 6, and 4.6 at 37 °C, Munter et al., 1999a) and 
fBQ-pG (at pH 7.4 at 37 °C for ten days, Franzén et al., 1998b) (Fig. 4). The yields 
of the adducts ranged between 0.1 – 0.9% depending on the pH. However, in the 
repeat study of Munter et al. (1999a), the adduct fBQ-pG (Franzén et al., 1998b) 
could not be detected. Guanine adducts are compatible with the concept that guanine 
seems to be the main target of MX in DNA (DeMarini et al., 1995; Hyttinen et al., 
1996; Knasmüller et al., 1996). However, the εfGuo-adduct was not detected in the 
reaction of MX with calf thymus DNA in vitro at a detection limit of five 
adducts/107 nucleotides (Munter et al., 1999a). This may indicate, that DNA lesions 
at guanine bases occur via a mechanism other than formation of stable DNA 
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adducts. There is as yet no evidence that any of these five adducts are formed in 
vivo. 
Formation of DNA adducts has not been observed in the reactions of MX with 
thymidine or cytidine (Munter et al., 1999a). 
CMCF, MCA, and MCF have also formed adducts. Incubation of calf thymus DNA 
at physiological pH and temperature for four days with CMCF, MCA, and MCF 
resulted in the formation of pfA-dR, εcA-dR, and fbaA-dR, respectively (Table 3). 
 
Table 3. DNA adducts in the reactions of CMCF, MCA, and MCF with calf thymus 
DNA. 
_________________________________________________________________________________________ 
CHF/adduct/yield/reference 
_________________________________________________________________________________________ 
 
CMCF 
 pfA-dR: 3-(2’-deoxy-β-D-ribofuranosyl)-7H-8-formyl[2,1-i]pyrimidopurine 
  6 adducts/105 nucleotides 
   (Munter et al., 1999b) 
----------------------------------------------------------------------------------------------------------------------- 
MCA 
 εcA-dR: 3-(2’-deoxyribofuranosyl)-7-formylimidazo[2,1-i]purine 
  5 adducts/106 nucleotides 
   (Le Curieux et al., 1997) 
----------------------------------------------------------------------------------------------------------------------- 
MCF 
 fbaA-dR: 4-(2’-deoxyribofuranosyl-N6-adenosinyl)-3-formyl-3-butenoic acid 
   4 adducts/105 nucleotides 
   (Le Curieux et al., 1997) 
_________________________________________________________________________________________ 
 
    
Incubation of MCA and MCF with nucleosides also resulted in the formation of  
many adducts (Kronberg et al., 1992; 1993; 1996; Asplund et al., 1995; Munter et 
al., 1996). 
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2.6.2 Mutations in vitro 
MX-induced mutations are directed primarily at GC sites in the DNA of bacteria and 
mammalian cells. In the hisG46 gene of the S. typhimurium strains TA100, TA1535, 
and TA1950 MX induced mainly GC→TA transversions (DeMarini et al., 1995; 
Hyttinen et al., 1995; Knasmüller et al., 1996). In strain TA100, MX induced to a 
lesser extent also GC→AT transitions (DeMarini et al., 1995). Most of these base-
pair substitution mutations were in the second position of the hisG46 (CCC) target 
codon. In the hisD3052 gene of strain TA98, MX induced 2-base deletions and 
complex frameshifts containing primarily GC→TA transversions at the 
CGCGCGCG site (DeMarini et al., 1995). In the hisG428 gene of strains TP2428 
and TA104, MX induced also mainly GC→TA transversions (target sequence TAA) 
and to a lesser extent AT→TA transversions (Knasmüller et al., 1996; Shaughnessy 
et al., 2000). In E. coli strains with different DNA repair capabilities MX induced 
frameshift mutations. The base-pair substitution mutations were mainly GC→TA 
transversions, but also to some extent GC→AT transitions were detected 
(Watanabe-Akanuma and Ohta, 1994). 
The mutational spectra by MX in mammalian cells is consistent with the mutational 
spectra in bacteria. In the hypoxanthine phosphoribosyl transferase (hprt) gene of 
CHO cells, most base-pair substitutions were GC→TA transversions. The remaining 
mutations consisted of AT→TA transversions and deletions of single GC base pairs 
(−1 frameshifts) (Hyttinen et al., 1996). The mutations involving GC→TA 
transversions are consistent with the ‘A’ rule that adenine nucleotides are 
preferentially added opposite to non-instructional lesions (Strauss, 1991). 
The mutational spectras induced by CMCF and MCF in S. typhimurium strain 
TA100 are almost identical with MX. Both chemicals induce primarily GC→TA 
transversions, in particular, at the second position of the hisG46 (CCC) target codon. 
In contrast, MCA evoked predominantly GC→AT transitions in the second position 
of the CCC codon in the hisG46 allele (Hyttinen et al., 1995; Knasmüller et al., 
1996). In strain TA104, more than half of the mutations induced by MCF were 
GC→TA transversions, most of the remaining revertants being AT→TA 
transversions (Shaughnessy et al., 2000). 
2.6.3 Thermodynamic mechanism 
Instead of DNA adduct formation, a thermodynamic mechanism as an alternative 
mechanism for the mutagenic activity of MX has been suggested (Tuppurainen, 
1997). There is, however, no evidence that this mechanism actually occurs in 
mammalian cells for MX. Studies on the electronic properties of MX have indicated 
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that the mutagenicity of MX in bacteria is mainly a manifestation of its electron-
accepting ability (Tuppurainen et al., 1991; 1992; Tuppurainen, 1992; Tuppurainen 
and Lötjönen, 1993). The mutagenicity of MX would depend on the electron affinity 
and the energy of the lowest unoccupied molecular orbital (Elumo). Mutagenicity 
would increase with decreasing LUMO energy i.e. with increasing electron affinity 
(Tuppurainen et al., 1991; 1992; LaLonde et al., 1992; Tuppurainen, 1992; 
Tuppurainen and Lötjönen, 1993). Thus, the mutagenesis would involve an electron 
transfer from a nucleophilic DNA base to the lowest empty molecular orbital of the 
MX compound. According to the hard-soft acid-base principle, soft electrophiles 
(e.g. MX) prefer to bind to soft nucleophiles. Thus, the most favourable interaction 
of MX would occur with guanine, because it is the softest of the DNA bases 
(Tuppurainen et al., 1992). The hot spot for the MX-induced mutations in S. 
typhimurium strain TA100 is the second position of the hisG46 target CCC codon 
(DeMarini et al., 1995; Hyttinen et al., 1995), which represents the global minimum 
energy position for a positive hole in ionized DNA. In the thermodynamic 
mechanism, MX-induced damage at DNA bases would involve a one-electron 
reduction as a key step leading to an ionized DNA base (e.g. CG+•) (Tuppurainen, 
1997). Thus, instead of site-specific binding or adduct formation, the potential 
mechanism to explain the mutagenic activity of MX would be thermodynamic in its 
nature. 
2.6.4 The promotion effect 
There is some evidence in vivo that MX may promote tumor development. MX had 
promoting effects on Wistar rat glandular stomach carcinogenesis after initiation 
with N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) and NaCl (Nishikawa et al., 
1999). After eight weeks of initiation with MNNG, MX was administered in the 
drinking water at concentrations of 0, 10, or 30 ppm for 57 weeks. The incidences of 
adenocarcinomas and atypical hyperplasias in the glandular stomach increased, 
when MX was given in the drinking water during the postinitiation phase. 
Furthermore, MX has exhibited enhancing effects on cell proliferation and lipid 
peroxidation in the glandular stomach mucosa of Wistar rats (Nishikawa et al., 
1994) and on cell proliferation in the glandular stomach of F344 rats (Furihata et al., 
1992), but a local irritating effect at the site of administration as a contributing factor 
could not be excluded in the latter study. Wistar and F344 rats were given MX via 
the drinking water (6.25, 12.5, 25, or 50 ppm for 5 weeks) or by gastric intubation 
(single dose at 10, 20, 30, or 60 mg/kg), respectively. MX did not lead to formation 
of tumors in the gastrointestinal tract when given via the drinking water to rats 
(Komulainen et al., 1997). 
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MX did not affect the development of the thyroid proliferative lesions in the 
promotion phase of the rodent two-stage thyroid carcinogenesis model (Son et al., 
2000a; 2000b). In the initiation phase, male and female F344 rats were given a 
single subcutaneous injection of N-bis(2-hydroxypropyl)nitrosamine (DHPN) and 
from one week after the DHPN initiation, MX was administered via the drinking 
water at a daily dose of 30 ppm for 12 weeks. MX treatment had no influence on 
thyroid weights, but the relative kidney weights were slightly increased in males 
(Son et al., 2000b). These observations are compatible with those made in Wistar 
rats (Komulainen et al., 2000). Thyroid glands are not sensitive to hyperplasia or 
cell proliferation after brief exposures to MX. 
In male Balb/cA mice, MX promoted the growth of aberrant crypt foci in colon but 
did not increase the number of foci, when the colon carcinogen azoxymethane was 
given intrarectally for six weeks and then MX (20 or 40 mg/kg) was administered 
for six or four weeks, respectively (Steffensen et al., 1999). The MX-exposure was 
rather short for the evaluation of a promoting effect in light of the experience with 
rats. 
The abnormally high tumor incidence in rats, and the finding of Nishikawa et al. 
(1999) on a possible tumor promotion effect for MX, stimulated further studies on 
MX as a tumor promotion using the two-stage mouse fibroblast cell transformation 
assay in vitro. In those studies, C3H 10T1/2 mouse fibroblasts (Laaksonen et al., 
2001) and Balb/c 3T3 mouse fibroblasts (Nakajima et al., 2005) were exposed to 3-
methylcholanthrene (MC) in the initiation phase and to MX during the promotion 
phase of the assay. MX promoted the development of the transformation foci in a 
dose-dependent manner in both cell lines. In the two-stage C3H 10T1/2 cell 
transformation assay, MCA and MCF, but not CMCF also enhanced the MC-
induced transformation foci formation (Laaksonen et al., 2003). MX, MCA, and 
MCF promoted the foci formation within the same concentration range (1.0 – 4.0 
µg/ml). 
In summary, the genotoxicity data on MX suggest that it is a genotoxic carcinogen. 
The high tumor incidence in certain tissues in rats indicates, however, that other 
mechanisms may have contributed to tumor development in the experimental 
studies. The data obtained in mammalian cells suggest that also the other CHFs, i.e. 
CMCF, MCA, and MCF may have properties that contribute to the cancer risk 
associated with drinking water.  
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3 AIMS OF THE STUDY 
The aim of this thesis was to study the cellular mechanisms of MX carcinogenicity 
in rats to evaluate the cancer risk of MX present in chlorinated drinking water. In the 
course of the studies, the work was expanded to other CHFs, because they proved to 
be nearly equally potent genotoxins in mammalian cells as MX. 
 
The more specific aims were: 
 
1. To analyze mutation spectras of the p53 and Ki-, Ha-, and N-ras genes in 
the MX-induced rat liver tumors to elucidate the role of point mutations in 
those genes in tumor development (I). 
2. To determine the expression of p53 and p21 Ki-ras proteins in the MX-
induced rat liver and thyroid gland tumors as an indication of altered 
activity in the pathways in which these proteins function (I and II). 
3. To define the effects of CHFs on GJIC as a possible mechanism of their 
ability to promote malignant foci formation (III and IV). 
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4 MATERIALS AND METHODS 
4.1 Rat tumor samples (I and II) 
The liver and the thyroid gland tumor samples for mutation and 
immunohistochemical analyses were obtained from the 104-week carcinogenicity 
study with MX in Wistar rats (Komulainen et al., 1997) (Table 4). Only tumors 
which were large enough to provide a sample were selected for further analysis. The 
samples represented all dose groups and both sexes but not every single tumor and 
animal presented in Table 4. The tissue samples had been preserved in 10% buffered 
formalin at the time of necropsy and embedded in paraffin blocks during the course 
of the regular histopathology. 
4.2 Mutation analyses (I) 
A total of 50 rat liver tumor samples (16 hepatocellular adenomas, 8 hepatocellular 
carcinomas, 23 cholangiomas, 3 cholangiocarcinomas) were examined in the 
mutation analyses of p53 and ras genes. The samples were representative for 
tumors, but contained also normal tissue. Exons 4-7 of p53 gene were amplified by 
polymerase chain reaction (PCR) and mutations in the exons were screened using 
single-strand conformation polymorphism (SSCP). Direct sequencing was used to 
verify the SSCP-suggested mutations. Mutation analyses of the PCR amplified 
exons 1-2 of Ki-, Ha-, and N-ras genes were performed using a combination of 
temperature gradient gel electrophoresis (TGGE), SSCP and DNA sequencing. The 
exons 4-7 of p53 and exons 1-2 of ras genes were chosen for mutation screening, 
because mutations in those exons are particularly common in a variety of tumors 
(Barbacid, 1987; Stanley, 1995; Perantoni and Rice, 1999). 
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Table 4. Rat liver and thyroid tumors in the MX carcinogenicity study (Komulainen et 
al., 1997). 
_________________________________________________________________________________________ 
                                                                                                                      MXa    
                                                                                    ______________________________________________ 
Sex/tissue/tumor type   Control            Low dose             Mid dose          High dose 
_________________________________________________________________________________________ 
 
Females 
 
 Liver 
  Adenoma 1b (2%)c 1 (2%) 1 (2%) 10 (20%) 
  Carcinoma 1 (2%) 1 (2%) 3 (6%) 0 
  Cholangioma 0 4 (8%) 10 (20%) 33 (66%) 
  Cholangiocarcinoma 1 (2%) 0 0 2 (4%) 
 
 Thyroid glands 
  Follicular adenoma 4 (8%) 16 (33%) 36 (72%) 36 (72%) 
  Follicular carcinoma 1 (2%) 3 (6%) 6 (12%) 22 (44%) 
  C-cell adenoma 11 (22%) 11 (22%) 10 (20%) 16 (32%) 
  C-cell carcinoma 0 0 0 1 (2%) 
 
Males 
 
 Liver 
  Adenoma 0 1 (2%) 2 (4%) 4 (8%) 
  Carcinoma 0 0 2 (4%) 1 (2%) 
  Cholangioma 0 0 1 (2%) 4 (8%) 
  Hepatocholangiocarcinoma 0 1 (2%) 0 0 
 
 Thyroid glands 
  Follicular adenoma 2 (4%) 20 (40%) 34 (68%) 21 (43%) 
  Follicular carcinoma 0 1 (2%) 9 (18%) 27 (55%) 
  C-cell adenoma 11 (22%) 7 (14%) 10 (20%) 11 (22%) 
  C-cell carcinoma 0 0 2 (4%) 0 
_________________________________________________________________________________________ 
aMX doses for females: 0.6 (low dose), 1.9 (mid dose), and 6.6 mg/kg (high dose), and for males: 0.4 (low 
dose), 1.3 (mid dose), and 5.0 mg/kg (high dose) (Komulainen et al., 1997). 
bNumber of animals with one or more tumors indicated. 
cFrequency of animals with tumor as percentage of examined animals. 
4.2.1 DNA extraction 
For DNA extraction, 30-µm sections were cut from paraffin-embedded blocks of the 
liver tumor tissues. DNA was extracted with the phenol-chloroform-isoamylalcohol 
method. DNA was dissolved in TE-buffer (10 mM Tris, 1 mM EDTA, pH 8.0) and 
kept at –20 °C until used in PCR. 
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4.2.2 Polymerase chain reaction (PCR) 
Amplification of the exons 4-7 of p53 and exons 1-2 of ras genes by PCR was 
carried out using the extracted DNA as the template. The procedure is described in 
detail in the original publication (I).  
4.2.3 Temperature gradient gel electrophoresis (TGGE) 
The TGGE mutation detection method can separate DNA fragments which differ at 
a single base pair site. The principle of this screening method is that a DNA 
fragment migrates into a polyacrylamide gel with a gradient of increasing 
temperature until it reaches a temperature which induces partial strand unwinding. 
As a consequence of being partially denatured, the DNA undergoes a decrease in its 
electrophoretic mobility. Homologous DNA fragments differing by a single base 
pair in the area of mutation migrate to different depths before undergoing abrupt 
changes in mobility (Wartell et al., 1998).  
TGGE and SSCP methods rely on the technique of PCR to amplify the region of 
DNA of interest. Thus, TGGE was carried out for the PCR products of ras genes 
using a Biometra TGGE system (Göttingen, Germany). Silver staining was used for 
visualization of the bands. 
4.2.4 Single-strand conformation polymorphism (SSCP) 
The principle of SSCP mutation detection method is based on the fact that the 
secondary structure of single-stranded DNA depends on the DNA sequence. 
Alterations in the secondary structure due to a single base change in the DNA 
sequence can modify the electrophoretic mobility of DNA fragment (Balogh et al., 
2004).  
SSCP was carried out for the PCR products of p53 gene and ras genes using a 
PhastGel electrophoresis system (Amersham Pharmacia Biotech, Uppsala, Sweden) 
and a Biometra TGGE system, respectively. Silver staining was used for 
visualization of the bands. 
4.2.5 Direct sequencing 
The PCR products of the p53 and ras genes were purified and the direct sequencing 
was performed as described in the original publication (I). 
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4.3 Immunohistochemical analyses (I and II) 
Expression of p53 protein was studied in 56 rat liver tumor samples (14 
hepatocellular adenomas, 8 hepatocellular carcinomas, 32 cholangiomas, 2 
cholangiocarcinomas) (I) and in 34 rat thyroid gland tumor samples (3 follicular 
adenomas, 29 follicular carcinomas, 2 C-cell carcinomas) (II) by 
immunohistochemical staining using the polyclonal antibody CM5 (Novocastra 
Laboratories, Newcastle-upon-Tyne, UK). Expression of p21 Ki-ras protein was 
evaluated in thyroid gland tumor sections (13 follicular carcinomas, one C-cell 
carcinoma) using the monoclonal antibody F234 (Santa Cruz Biotechnology, Santa 
Cruz, CA) (II). CM5 and F234 are assumed to detect both mutated and wild-type 
p53 and p21 Ki-ras, respectively. 
Five micrometer thick sections were cut from paraffin-embedded tissue blocks. 
Sections were immunohistochemically stained for p53 or p21 Ki-ras protein using 
the standard avidin-biotin-peroxidase complex method (ABC Vectastain Elite Kit, 
Vector Laboratories Inc., Burlingame, CA). The samples were considered p53- or 
p21 Ki-ras-positive when ≥10% cells in the entire tumor area expressed the protein. 
4.4 Analyses of gap junctional intercellular communication 
(GJIC) (III and IV) 
4.4.1 Cell cultures 
Two cell lines were used for the analyses of GJIC. The experiments were done first 
using Balb/c 3T3 mouse fibroblast cells (clone A31) (III), because the CHFs 
showed promotion potential in mouse fibroblasts (Laaksonen et al., 2001; 2003). To 
confirm the results in the target cells for MX-induced tumorigenicity, WB-F344 rat 
liver epithelial cells were used (IV). The Balb/c 3T3  and WB-F344 cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, UK) and 
Eagle’s Minimum Essential Medium (EMEM) (Sigma, St. Louis, MO) with the 
supplements, respectively, at 37 °C in an atmosphere of 5% CO2. 
4.4.2 Chlorohydroxyfuranones (CHFs) 
MX was synthesized by Radian International (Austin, TX). CMCF and MCF were 
synthesized as described by Franzén and Kronberg (1995). MCA was from Sigma-
Aldrich (Steinheim, Germany). The chemical structures of the compounds are 
shown in Fig. 2. 
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4.4.3 Scrape-loading dye transfer (SL/DT) assay 
The effects of CHFs on GJIC were studied using the SL/DT assay (El-Fouly et al., 
1987). The cells were grown to near confluence in 60-mm culture dishes and the 
medium was replaced with fresh medium containing the chemical at the desired 
concentration. The concentrations and exposure times of CHFs and 12-O-
tetradecanoylphorbol-13-acetate (TPA) (positive control) used in the assay are 
summarized in Table 5. The viability of the cell cultures was determined using the 
Trypan blue dye exclusion (TBDE) test. After the exposure, a Lucifer yellow dye 
solution (Sigma) was added and the cells were scraped using a razor blade. After 
dye incubation, the cells were fixed with formaldehyde. The migration of Lucifer 
yellow dye from the scrape line was examined with an epifluorescence microscope. 
GJIC was determined by counting the total number of fluorescence stained cells next 
to the scrape line (III) or by measuring the distance of the dye transfer from the 
scrape line (IV). 
 
Table 5. Concentrations and exposure times of CHFs and TPA (positive control) in the 
SL/DT assay. 
_________________________________________________________________________________________ 
 Concentrations (µM) Exposure times (h) 
                                                           __________________________________________________________ 
 
Balb/c 3T3 cells (III): 
 
 MX 0.005, 0.05, 5, 50 0.25, 0.5, 1, 2, 3, 6 
 CMCF 50, 75, 100, 125 0.5, 3, 6 
 MCA 0.05, 0.5, 5, 50 0.5, 3, 6 
 MCF 100, 250, 625, 1562.5 0.5, 3, 6 
 TPA 0.002, 0.008, 0.032, 0.128, 8 0.5 
 
WB-F344 cells (IV): 
 
 MX 1.875, 3.75, 7.5, 15 1, 12 
 CMCF 6.25, 12.5, 25, 50 1, 12 
 MCA 10, 20, 40, 80 1, 12 
 MCF 50, 150, 450, 1350 1, 12 
 TPA 0.01 1, 12 
_________________________________________________________________________________________ 
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4.4.4 Enzyme inhibitors (IV) 
To investigate the role of protein kinase C (PKC) and mitogen-activated protein 
kinase (MAPK) signaling pathways on the inhibition of GJIC by CHFs in WB-F344 
cells, the enzyme inhibitors GF109203X (bisindolylmaleimide 1) (Sigma) and 
PD98059 (Sigma) were used to block the activity of the PKC and MAPK, 
respectively, before exposure to CHFs. GF109203X inhibits the isozymes PKC α, 
βI, βII, γ, δ, and ε (Gekeler et al., 1996). No specific inhibitor of MAPK was 
available, but PD98059 is a specific inhibitor of MEK 1, which is the direct 
upstream activator kinase of the MAPK (Dudley et al., 1995). 
4.4.5 Western blot (IV) 
Western blot analysis was performed to determine the involvement of 
phosphorylation of connexin43 (Cx43) protein in the inhibition of GJIC by CHFs in 
WB-F344 cells. The analysis was performed as described by Trosko et al. (2000). 
After CHF exposure, the cells were lysed and protein samples were subjected to 
sodium dodecylsulphate – polyacrylamide gel electrophoresis (SDS-PAGE). 
Proteins were transferred electrophoretically to a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad, Hercules, CA). Cx43 was detected with polyclonal rabbit anti-
connexin 43 (Zymed Laboratories Inc., San Francisco, CA) as the primary antibody 
and alkaline phosphatase-conjugated goat anti-rabbit IgG (Zymed) as the secondary 
antibody using the 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium 
(BCIP/NBT) (Bio-Rad) colorimetric method. 
4.4.6 Reverse transcription-polymerase chain reaction (RT-PCR) (IV) 
RT-PCR was performed to analyze Cx43 mRNA levels in WB-F344 cells after CHF 
exposure. Total RNA was isolated using GenElute™ Mammalian Total RNA 
Miniprep Kit (Sigma). cDNA synthesis was performed using Omniscript reverse 
transcriptase (Qiagen, Hilden, Germany) and random hexamers (Roche, Mannheim, 
Germany). After cDNA synthesis, PCR was carried out using DyNAzyme™ II DNA 
polymerase (Finnzymes, Espoo, Finland) and Cx43-primers (forward: 5’-
GCGTGAGGAAAGTACCAAAC-3’; reverse: 5’-
GTGAAGCCGCCGCCAAAGTTG-3’). 
4.5 Measurement of caspase-3-like protease activity (III) 
The effects of MX on apoptosis were detected by the measurement of caspase-3-like 
protease activity. The Balb/c 3T3 cells were grown to near confluence in 60-mm 
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culture dishes and the medium was replaced with fresh medium containing MX 
(0.05, 5, 50, 100, 200, 800, and 2000 µM) at the desired concentration. After the 
exposure (1, 2, or 6 h), the caspase-3-like protease activity was measured as 
described by Movsesyan et al. (2002). The cleavage of the fluorogenic substrate, 
Ac-DEVD-AMC, was measured fluorometrically with a Perkin-Elmer HTS7000 
Plus fluorescence plate reader at an excitation wavelength of 380 nm and an 
emission wavelength of 465 nm. 
4.6 Statistical analyses (III and IV) 
The concentration-dependent inhibition and the recovery of the inhibition of GJIC 
by CHFs, and caspase-3 activity by MX were tested using one-way ANOVA 
followed by Tukey or Dunnett post hoc test (SPSS for Windows version 10.1 or 
12.0.1; SPSS, Inc., Chicago, IL). The effects of PKC inhibitor and MEK 1 inhibitor 
on the inhibition of GJIC by CHFs were analyzed using the nonparametric Mann-
Whitney test (SPSS). 
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5 RESULTS 
5.1 Mutation analyses (I) 
5.1.1 p53 gene 
Fifty rat liver tumors of the MX carcinogenicity study were analyzed. Of those, two 
hepatocellular adenomas and one cholangiocarcinoma had four mutations in the p53 
gene (Table 6). Three of the four mutations were GC→AT transitions and one 
mutation was a AT→TA transversion. All mutations occurred in tumors from the 
high dose female group. The mutations exhibited no consistent pattern, scattering to 
different codons and positions of the codon. 
 
Table 6. Mutations in p53 gene in liver tumors of Wistar rats in the MX carcinogenicity 
study. 
_________________________________________________________________________________________ 
 
Tumor Nucleotide Exon Codon Predicted amino 
 substitution   acid change 
_________________________________________________________________________________________ 
 
Adenoma GTG→ATG 5 176 Val→Met 
 CGG→CGA 7 265 Arg→Arg 
 
Adenoma AAT→TAT 7 286 Asn→Tyr 
 
Cholangiocarcinoma CGC→CAC 5 173 Arg→His 
_________________________________________________________________________________________ 
 
5.1.2 ras genes 
Screening of the mutations in exons 1 and 2 of the Ki-, Ha-, and N-ras revealed no 
mutations in any of the 50 rat liver tumors. 
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5.2 Immunohistochemical analyses (I and II) 
5.2.1 Rat liver tumors (I) 
Of the analyzed tumors, all of the cholangiomas (32) and cholangiocarcinomas (2), 
but not the hepatocellular adenomas (14) or carcinomas (8) overexpressed p53 
protein. Cholangiomas and cholangiocarcinomas originate from the bile duct 
epithelial cells. The epithelial cells of the hyperplastic bile ducts of old rats 
overexpressed p53 independently of the MX treatment. Livers of the younger rats 
(up to 24 weeks) did not express p53 protein. Furthermore, MX treatment of the 
younger rats (30 mg/kg for 18 weeks or 10 mg/kg for 1 or 3 weeks) did not induce 
expression of the p53 protein. Thus, overexpression of p53 in the bile ducts 
appeared to be related to the age of the Wistar rats, not to the exposure to MX. 
5.2.2 Rat thyroid gland tumors (II) 
In most of the studied rat thyroid gland tumor samples there was no expression of 
the p53 protein. Six follicular carcinomas (21% of those studied) and one C-cell 
carcinoma (50%) expressed some p53 staining (1-5% of cells positive), but they 
were not interpreted as being p53-positive. p21 Ki-ras protein expression was not 
observed in any of the studied 14 thyroid gland tumors, which included also the 
samples containing some p53 expression. 
5.3 Analyses of gap junctional intercellular communication 
(GJIC) (III and IV) 
Concentration- and time-responses for inhibition of GJIC by CHFs were determined 
in Balb/c 3T3 (III) and WB-F344 cells (IV). The involvement of the PKC and 
MAPK signaling pathways on the inhibition of GJIC by CHFs was studied in WB-
F344 cells (IV). In addition, the effects of CHFs on Cx43 protein and mRNA levels 
were analyzed in WB-F344 cells (IV). 
In general, GJIC was dose-dependently decreased by all studied CHFs in both cell 
lines. The orders of the potency to inhibit GJIC in Balb/c 3T3 and WB-F344 cells 
were MX>MCA>CMCF>MCF and MX>CMCF≈MCA>MCF, respectively. 
However, there were major differences in the potencies and the ranges of the active 
concentrations of the CHFs between the Balb/c 3T3 and WB-F344 cells. Therefore, 
their effects are summarized compound by compound. 
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5.3.1 Effects of MX on GJIC 
In Balb/c 3T3 cells MX inhibited GJIC at nanomolar concentrations. This inhibition 
occurred at the lowest in vitro concentrations observed for any MX-induced effect in 
mammalian cells so far. The active concentration range was wide. After a 30-min 
treatment at 5 nM, the inhibition of GJIC was 16% and the maximum inhibition 
(50%) was achieved at 50 µM. After an extended exposure time (up to 6 h), there 
was some recovery in GJIC (Fig. 5) (III). 
Figure 5. Concentration-dependent inhibition of GJIC by MX (mean values ± SEM) in 
Balb/c 3T3 cells. ***p<0.001, statistically significant difference to negative control 
(Tukey post-hoc test); ##p<0.01, ###p<0.001, statistically significant difference to 30 min 
of MX exposure (Dunnett post-hoc test). 
 
In WB-F344 cells, the active concentration range for MX was narrow. After 1 h of 
exposure at 1.875 µM, the inhibition of GJIC was 19%, while the maximum 
inhibition at 15 µM was 85%. The inhibition of GJIC by MX was similar after 12 h 
of exposure as that seen at 1 h (Fig. 6) (IV). 
The MX-induced inhibition of GJIC was a reversible process. When after 1 h of 
CHF exposure, the WB-F344 cells were incubated in CHF-free medium for up to 8 
h, then GJIC recovered slowly (Fig. 6) (IV). 
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The PKC inhibitor GF109203X had no effect on the inhibition of GJIC by MX in 
WB-F344 cells, but the MEK 1 inhibitor PD98059 (50 µM, with 5 min pre-
exposure) almost completely abolished the inhibitory effect of MX (Fig. 6). Thus, 
MAPK signaling pathway was involved in the inhibition of GJIC by MX (IV). 
 
 
Figure 6. Concentration-dependent inhibition of GJIC by MX (mean values ± SEM), its 
recovery and effects of MX in combination with the MEK 1 inhibitor on GJIC in WB-
F344 cells. **p<0.01, ***p<0.001, statistically significant difference to negative control 
(Dunnett post-hoc test); ###p<0.001, statistically significant difference to 1 h of MX 
exposure (Dunnett post-hoc test); &&p<0.01, statistically significant difference to MX 
exposure alone (Mann-Whitney test). 
 
Three major isoforms of Cx43 protein ranging from unphosphorylated (P0) to 
increased phosphorylated states (P1, P2) are detectable by Western blot analyses 
(Matesic et al., 1994). No increases in the basal phosphorylation state of the Cx43 
protein were observed in WB-F344 cells after 1 h of exposure to concentrations of 
MX which inhibited GJIC. In contrast, the levels of all three isoforms of Cx43 were 
reduced in a concentration-dependent fashion. The Cx43 protein almost completely 
disappeared after exposure with the highest MX concentration. However, MX 
caused no appreciable changes in Cx43 mRNA levels in WB-F344 cells. 
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5.3.2 Effects of CMCF on GJIC 
In terms of the observed lowest effective concentration, CMCF was a 10,000-fold 
weaker inhibitor of GJIC in Balb/c 3T3 cells than MX. The range of active 
concentrations was narrow. After 30 min of CMCF treatment, a slight inhibition was 
seen at 50 µM (18%) and the maximum inhibition (50%) was attained at 125 µM. 
During the extended exposure time (up to 6 h), the inhibition of GJIC by CMCF 
became stronger (III). 
In WB-F344 cells, the potency of CMCF to inhibit GJIC was 3.3-fold weaker than 
that of MX, in terms of the observed lowest effective concentration. The dose-
response curve was steep as in Balb/c 3T3 cells. The concentrations needed to 
inhibit GJIC in WB-F344 cells (Fig. 7) were lower than in Balb/c 3T3 cells. The 
inhibition was 16% after 1 h of incubation at 6.25 µM. Maximal inhibition (70%) 
occurred at 50 µM. As in the case of MX, the inhibition of GJIC by CMCF was 
continuously down regulated following prolonged exposure (12 h), but the 
communication was re-established gradually, when CMCF was removed from the 
system (Fig. 7) (IV). 
The inhibitory effect of CMCF was reversed by the MEK 1 inhibitor (Fig. 7), but 
not by the PKC inhibitor, i.e. activation of MAPK signaling pathway is necessary 
also for the inhibition of GJIC by CMCF in WB-F344 cells (IV). 
The expression of Cx43 protein decreased in a concentration-dependent manner up 
to total loss at 50 µM CMCF, but the mRNA levels did not change (IV). 
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Figure 7. Concentration-dependent inhibition of GJIC by CMCF (mean values ± SEM), 
its recovery, and effects of CMCF in combination with the MEK 1 inhibitor on GJIC in 
WB-F344 cells. ***p<0.001, statistically significant difference to negative control 
(Dunnett post-hoc test); ###p<0.001, statistically significant difference to 1 h of CMCF 
exposure (Dunnett post-hoc test); &&p<0.01, statistically significant difference to CMCF 
exposure alone (Mann-Whitney test). 
5.3.3 Effects of MCA on GJIC 
MCA was a 10 times weaker inhibitor of GJIC in Balb/c 3T3 cells than MX. Like 
MX, MCA exhibited a wide concentration range. A slight inhibition (18%) appeared 
at 50 nM after 30 min exposure and the maximum inhibition (50%) was achieved at 
50 µM. There was some recovery in GJIC after the 6 h exposure period (III). 
In WB-F344 cells, MCA was a 5.3-fold less potent inhibitor of GJIC than MX, in 
terms of the observed lowest effective concentration. Unlike in Balb/c 3T3 cells, the 
range of active concentrations was narrow. After 1 h of exposure, GJIC was 
inhibited by MCA from 10 µM (22%) to a maximum at 80 µM (70%). After 
prolonged treatment (12 h), clearly lower concentrations of MCA inhibited GJIC 
(Fig. 8). GJIC recovered at 40 µM MCA in MCA-free medium, but not at 80 µM 
(Fig. 8), which was already cytotoxic (IV). 
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The MEK 1 inhibitor counteracted the inhibitory effect of MCA on cell 
communication (Fig. 8), whereas the PKC inhibitor had no effect. Thus, MAPK 
signaling pathway also participates in the MCA-induced inhibition of GJIC in WB-
F344 cells (IV). 
MCA treatment also resulted in a reduction in the expression of Cx43 protein. A 
complete loss of the expression was observed at 80 µM MCA. However, there were 
no alterations in the Cx43 mRNA levels (IV). 
Figure 8. Concentration-dependent inhibition of GJIC by MCA (mean values ± SEM), 
its recovery, and effects of MCA in combination with the MEK 1 inhibitor on GJIC in 
WB-F344 cells. *p<0.05, ***p<0.001, statistically significant difference to negative 
control (Dunnett post-hoc test); ###p<0.001, statistically significant difference to 1 h of 
MCA exposure (Dunnett post-hoc test); &&p<0.01, statistically significant difference to 
MCA exposure alone (Mann-Whitney test). 
5.3.4 Effects of MCF on GJIC 
MCF was the weakest inhibitor of GJIC in both cell lines. In Balb/c 3T3 (III) and 
WB-F344 cells (IV), MCF was 20,000- and 26.7-fold, respectively, weaker inhibitor 
than MX. The ranges of the active concentrations to inhibit GJIC were similar in 
both cell lines (100 – 1562.5 µM for Balb/c 3T3 and 50 – 1350 µM for WB-F344). 
Also in both cell lines, the inhibition of GJIC became stronger after prolonged MCF 
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treatments. After inhibition by MCF, GJIC reappeared in WB-F344 cells in MCF-
free medium (Fig. 9). 
The inhibitory effect of MCF was abolished by the MEK 1 inhibitor (Fig. 9), but not 
by the PKC inhibitor, i.e. the MAPK signaling pathway is involved also on the 
inhibition of GJIC by MCF in WB-F344 cells (IV).  
A concentration-dependent reduction in the levels of all three isoforms of Cx43 
protein was observed without any changes in Cx43 mRNA levels also after MCF 
treatment. A total loss of Cx43 expression was seen at 1350 µM MCF (IV).  
 
 
Figure 9. Concentration-dependent inhibition of GJIC by MCF (mean values ± SEM), 
its recovery, and effects of MCF in combination with the MEK 1 inhibitor on GJIC in 
WB-F344 cells. **p<0.01, ***p<0.001, statistically significant difference to negative 
control (Dunnett post-hoc test); ###p<0.001, statistically significant difference to 1 h of 
MCF exposure (Dunnett post-hoc test); &p<0.05, &&p<0.01, statistically significant 
difference to MCF exposure alone (Mann-Whitney test). 
 
The main findings of the GJIC analyses are summarized in Table 7. 
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Table 7. The effects of CHFs on GJIC, Cx43 protein, and PKC and MAPK signaling 
pathways. 
_________________________________________________________________________________________ 
 
                               MX CMCF MCA MCF 
_________________________________________________________________________________________ 
 
Balb/c 3T3 cells (III) 
 
 The effective concentration 0.05 – 50  75 – 125  0.5 – 50  250 – 1562.5 
 range (µM) for the inhibition 
 of GJIC (30 min exposure) 
---------------------------------------------------------------------------------------------------------------------- 
 WB-F344 cells (IV) 
 
 The effective concentration 1.875 – 15  6.25 – 50  10 – 80  50 – 1350 
 range (µM) for the inhibition 
 of GJIC (1 h exposure) 
 
 Recovery of GJIC GJIC recovered in CHF-free medium. 
 
 The activation of PKC no no no no 
 signaling pathway 
 
 The activation of MAPK yes yes yes yes 
 signaling pathway 
 
 Effect on Cx43 mRNA level CHFs caused no change in the level of Cx43 mRNA. 
 
 Phosphorylation of Cx43  CHFs did not increase the basal phosphorylation state of the 
 protein Cx43 protein. 
 
 Expression of Cx43 protein CHFs caused a concentration-dependent degradation of Cx43 
  protein. 
_________________________________________________________________________________________ 
 
 
5.3.5 Cytotoxicity of CHFs in GJIC analyses 
In Balb/c 3T3 cells, no cytotoxicity was observed at the concentrations of CHFs and 
exposure periods used (TBDE test) (III). In WB-F344 cells, no cytotoxicity was 
evoked by CHFs (TBDE test) after 1 h of exposure at the concentrations used, but 
incubations for 12 h with 50 µM CMCF, 40 µM MCA, 80 µM MCA, or 1350 µM 
MCF were cytotoxic to the extent that the GJIC analyses could not be performed 
(IV).  
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5.4 Apoptosis (III) 
Since GJIC and apoptosis are interrelated, the effects of MX on apoptosis were 
measured in Balb/c 3T3 cells. MX evoked apoptosis at concentrations 2000 – 4000-
fold higher than those needed to inhibit GJIC. There seemed to be a time-dependent 
concentration window. After 2 h of exposure, an increase in caspase-3 activity 
appeared only at the 200 µM concentration. Almost all cells were undergoing 
necrosis at 2000 µM. After 6 h, the increase in caspase-3 activity occurred also at a 
slightly lower concentration of 100 µM. The majority of the cells were necrotic if 
exposed to 800 µM. 
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6 DISCUSSION 
Epidemiological evidence indicates that the consumption of chlorinated drinking 
water increases the risk of cancer (Cantor et al., 1987; Morris et al., 1992; 1995; 
Koivusalo et al., 1994; 1995; 1997; Doyle et al., 1997; Villanueva et al., 2004). The 
detrimental health effects are suspected to be due to some of the several hundreds of 
different types of organic by-products of chlorination. One candidate group to 
contribute to the cancer risk in chlorinated drinking water is the CHFs. Of the CHFs, 
MX is known to be carcinogenic in Wistar rats (Komulainen et al., 1997) but the 
mechanism(s) to account for the carcinogenicity is/are not known. An improved 
understanding of the mechanisms of tumor induction would be important in human 
cancer risk assessment. Therefore, in this thesis, the main goal was to gain insight 
into the mechanisms behind MX tumorigenicity.  
In general, carcinogens can be classified as being either genotoxic (initiating agents) 
or nongenotoxic (promoting agents). However, many chemicals may act both via 
genotoxic and nongenotoxic mechanisms, i.e. they are complete carcinogens. 
Complete carcinogens may have effects at any stage of the carcinogenesis process 
(Pitot and Dragan, 1991). Besides the fact that many chemical carcinogens operate 
via a combination of mechanisms, their primary mechanism of action may vary also 
depending on the target tissues (Barrett, 1993). Thus, according to current 
knowledge, the multistage model of chemical carcinogenesis (initiation-promotion-
progression) (Fig. 1) may have limitations in fully describing the carcinogenesis 
process. 
In order to evaluate the genotoxic potential of MX in rats, mutation and 
immunohistochemical analyses were performed on the MX-induced liver and 
thyroid gland tumors, which were the main target organs of the MX tumorigenesis in 
Wistar rats (Komulainen et al., 1997). Due to observation that MX had potential to 
promote tumor development in vitro (Laaksonen et al., 2001), the nongenotoxic 
potential of MX was evaluated by performing GJIC studies in vitro. The cellular 
effects of MX in carcinogenesis observed in the current study are presented in 
Figure 10. 
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Figure 10. An illustration of cellular effects of MX in carcinogenesis observed in 
this study. Initiation phase: MX did not induce point mutations in p53 and ras genes, 
though it is a genotoxic compound. The target genes may be genes other than p53 or ras 
genes and also “spontaneous” mutations may arise. Promotion phase: MX promotes the 
initiated cell by activating an unknown factor(s), which leads to the activation of the 
MAPK signaling pathway. That, in turn, leads to the decreased expression of Cx43 
protein, which results in the inhibition of GJIC. Down-regulation of GJIC could favour 
the development and growth of the initiated cells into tumor cells. 
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6.1 Mutation analyses (I) 
An inherent potential to damage DNA is a characteristic of genotoxic carcinogens. 
In chemical carcinogenesis, mutations in oncogenes and/or tumor suppressor genes 
are thought to play a major role in the neoplastic process (Bertram, 2001). In the 
present study, the mutation analyses were focused on ras oncogenes (Ki-, Ha-, and 
N-ras) and the p53 tumor suppressor gene. Ras genes were selected for analyses, 
because ras mutations are often found in chemically-induced rodent tumors 
(Stanley, 1995; Sills et al., 1999; Takahashi and Wakabayashi, 2004). However, 
mutation analyses of the MX-induced liver tumors revealed no mutations in ras 
genes. The findings thus suggest that abnormal activation of ras genes is unlikely to 
be involved in the MX-induced rat liver carcinogenesis (Fig. 10). 
The p53 tumor suppressor gene, which is evolutionary highly conserved on the 
DNA sequence and protein function level and is involved in many cellular 
pathways, is an important hallmark of the cellular response to genotoxic stress 
(Pluquet and Hainaut, 2001). Alterations in the p53 gene are the most common 
genetic lesions observed in various human cancers (Hainaut and Holstein, 2000). 
The mutation frequencies of p53 are lower in rodent tumors compared to human 
tumors (Stanley, 1995; Miller, 1999). Inactivation of the p53 gene has been reported 
in chemically-induced rat liver tumors (Vancutsem et al., 1994; Barbin et al., 1997; 
Masui et al., 1997; Fu et al., 2003; Deng et al., 2004). The MX-induced liver tumors 
had only four mutations in the p53 gene in exons 4-7 (which correspond to human 
exons 4-8). Three of the four mutations were GC→AT transitions and the fourth was 
an AT→TA transversion, which is not compatible with the in vitro observations. In 
bacteria and in CHO cells, MX has induced predominantly GC→TA transversions 
(DeMarini et al., 1995; Hyttinen et al., 1995; 1996; Knasmüller et al., 1996), but 
these types of mutations were not observed in the liver tumors. Moreover, the 
mutations in the liver tumors scattered to different codons and positions of the 
codon. Thus, they exhibited no specific pattern. Mutations in the p53 gene are found 
in the progression stage of chemical carcinogenesis (Stanley, 1995; Barbin, 1997; 
Matsumoto et al., 1997; Miller, 1999). In this study, three mutations occurred in a 
benign tumor (hepatocellular adenoma) and only one in a malignant tumor 
(cholangiocarcinoma), however, all of these were found in females of the highest 
MX dose group. Thus, there was no clear association between mutations and tumor 
malignancy. These observations together suggest that mutations of the p53 gene do 
not play a major role in MX-induced liver carcinogenesis in rats (Fig. 10). 
The sensitivity of SSCP to detect mutations is 80 – 85% (Bassett et al., 1998; 
Yamanoshita et al., 2005). TGGE is more sensitive in detecting mutations, but it is 
not 100% sensitive (Hass et al., 2000; Frayling, 2002). It is thus possible that all 
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mutations were not detected but since the detected frequencies were very low, it is 
most unlikely that possible limitations in the sensitivity of the methods would 
explain the negative results. 
6.2 Immunohistochemical analyses (I and II) 
The expression of the p53 protein supports the finding of the mutation analysis. 
Immunohistochemical analyses were performed to address the role of p53 protein in 
the MX-induced liver and thyroid tumors and the role of p21 Ki-ras protein in MX-
induced thyroid tumors. In general, normal tissue expresses relatively low levels of 
p53 protein which are often undetectable when examined by immunohistochemical 
techniques. Instead, mutant p53 proteins (usually missense mutations) are stabilized 
against intracellular degradation and have prolonged half-lives compared to the 
short-lived wild-type proteins. Thus, intracellular p53 accumulations, as detectable 
by immunohistochemical analyses, are believed to be indicative of a DNA damage 
response and to represent long-lived mutant proteins. However, positively staining 
tumors are occasionally found that do not carry missense mutations and vice versa, 
pointing to alternative mechanisms whereby p53 can be stabilized. Thus, 
immunoreactivity is only an approximate indicator of the tumors with altered p53 
function (Harris and Hollstein, 1993).  
Several genotoxic carcinogens evoke a rapid overexpression of p53 in rat liver (van 
Gijssel et al., 1997; Wirnitzer et al., 1998; Nyska et al., 2002). In the current study, 
no overexpression of p53 protein appeared in the MX-induced hepatocellular 
adenomas and carcinomas, or in the liver after short-term treatments with MX. Even 
the hepatocellular adenomas carrying a p53 mutation, did not overexpress p53 
protein. In contrast, all the bile duct tumors, cholangiomas and 
cholangiocarcinomas, expressed p53 protein, although only one cholangiocarcinoma 
contained a p53 mutation. However, the expression of p53 might not be related at all 
to MX, but rather to the age of rats, because the epithelial cells of the hyperplastic 
bile ducts of aged rats overexpressed p53 protein independently of MX treatment. 
As yet unknown factor(s) maintained overexpression of p53 in the bile ducts in aged 
animals. There is the possibility that those factors can render bile ducts susceptible 
to MX-induced tumorigenesis. 
Mostly chemically-induced thyroid gland tumors in rats are caused by the blood 
thyroid stimulating hormone (TSH)-mediated hormonal promotion (Thomas and 
Williams, 1991; McClain, 1995). However, MX did not alter TSH and thyroid 
hormones thyroxine (T4) and triiodothyronine (T3) levels in rats after short-term (1 
week and 3 weeks) or long-term (104 weeks) administration (Komulainen et al., 
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1997; 2000). Thus, other mechanisms must be involved in the development of MX-
induced tumors in thyroid glands in rats. 
Expression of activated wild-type or oncogenic ras proteins can be detected in the 
premalignant as well as the malignant phase. In malignant tumors, oncogenic ras 
protein is dominant over wild-type ras (Malumbres and Pellicer, 1998; Singh et al., 
2005). Activation of wild-type ras protein can lead to uncontrolled proliferation also 
in the absence of a mutation. Wild-type ras protein can also antagonize the function 
of oncogenic ras, but the exact role of wild-type ras protein in growth arrest remains 
unresolved (Singh et al., 2005). Activation of ras oncogenes has been detected both 
in human and rat thyroid tumors (Lemoine et al., 1988; 1989; Suarez et al., 1990; 
Kitahori et al., 1995; 1996; 1997; Mizukami et al., 1995; Haugen et al., 1999; Motoi 
et al., 2000; Kobayashi et al., 2002). A correlation between the immunoreactivity of 
the ras oncogene product and the extent of ras mutations has been detected in the 
thyroid carcinomas of man (Motoi et al., 2000). It was not possible to perform 
reliable mutation analyses of the MX-induced thyroid gland tumors, because not 
enough DNA could be extracted from the specimens on the glass slides. The MX-
induced malignant thyroid tumors did not have abnormal expression of p21 Ki-ras 
protein. Also the response for p53 protein was interpreted as negative. These 
observations together suggest that the alterations in p53 and Ki-ras gene may not 
play major roles in the MX-induced thyroid tumorigenesis. The mutation and 
immunohistochemical analyses indicated that molecular pathways that do not 
involve inactivation of p53 or abnormal activation of ras genes mediate the MX-
induced liver and thyroid gland tumorigenesis in rats. 
6.3 Gap junctional intercellular communication (GJIC) (III-IV) 
Several nongenotoxic chemicals, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), phenobarbital, saccharin, and peroxisome proliferators, have been 
proposed to promote the carcinogenic process by acting epigenetically, that is, by 
causing alterations in the expression of the information of the genome at the 
transcriptional or posttranscriptional levels (Trosko and Upham, 2005). There is 
some indication that MX has promoting effects in vivo on Wistar rat glandular 
stomach carcinogenesis (Nishikawa et al., 1999) and MX, MCA, and MCF all 
promote the development of the transformation foci in vitro in the two-stage mouse 
fibroblast cell (C3H 10T1/2) transformation assay pretreated with MC (Laaksonen et 
al., 2001; 2003). 
One mechanism involved in the tumor-promotion is postulated to be down-
regulation of GJIC (Yotti et al., 1979). GJIC has a crucial physiological role in the 
maintenance of tissue homeostasis (Trosko and Ruch, 1998). Disruption of GJIC 
  
58 
results in loss of homeostatic control and could ultimately be a cause of promotion 
of tumors (Trosko et al., 1998). The reversible inhibition of GJIC has been 
demonstrated to be a common phenomenon evoked by many chemical tumor 
promoters (Trosko and Chang, 1988). Therefore, the effects of CHFs on GJIC were 
investigated. The work was started in mouse Balb/c 3T3 fibroblast cells in which 
MX was known to promote malignant foci formation. 
6.3.1 MX 
MX enhanced the foci formation both during the initiation and the promotion phase 
of the two-stage cell transformation assay (Laaksonen et al., 2001). The lowest 
effective concentration in mouse fibroblast cells (C3H 10T1/2) was 4.6 µM MX. 
Interestingly, the inhibition of GJIC by MX in mouse fibroblast cells (Balb/c 3T3) 
appeared already at nanomolar concentrations, i.e. at levels clearly below 4.6 µM. 
Actually, the inhibitory effect occurred at the lowest concentrations for MX to cause 
any effect in mammalian cells in vitro so far (Table 8). Thus, the inhibition of GJIC 
may be one mechanism involved in the promotion of the malignant foci formation 
by MX. However, the maximum inhibition of GJIC in Balb/c 3T3 cells was only 
50%. Balb/c 3T3 cells express Cx43 and Cx32 (Fang et al., 2001). The 50% 
maximum inhibition could be explained by preferential inhibition of only one type 
of gap junction, but this is mere speculation and cannot be confirmed from the 
current results. 
Since MX was a potent inhibitor of GJIC in Balb/c 3T3 cells, it raised the intriguing 
question of whether inhibition of GJIC could be detected also in the target cells of 
MX tumorigenicity. Thus subsequent GJIC studies were focused on rat liver 
epithelial cells (WB-F344). MX inhibited GJIC also in WB-F344 cells in a dose-
dependent fashion. The observation was confirmed recently by another group 
(Nishikawa et al., 2006). In the present study, after 1 h of MX exposure, cell 
coupling recovered slowly in MX-free medium indicating that this was a reversible 
effect. There was, however, no essential change in the Cx43 mRNA level. Thus, the 
mechanisms for the alterations of GJIC induced by MX were posttranscriptional. 
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Table 8. The effective concentration ranges of CHFs in mammalian cells in GJIC and 
genotoxicity studies in vitro.a) 
_________________________________________________________________________________________ 
 
                                              The effective concentration range (µM) 
                                                                           ___________________________________________________ 
 
Endpoint MX CMCF MCA MCF 
_________________________________________________________________________________________ 
 
Inhibition of GJIC 0.05 – 50  75 – 125  0.5 – 50 250 – 1562.5 
(Balb/c 3T3 cells)(III)  
 
Inhibition of GJIC 1.875 – 15 6.25 – 50 10 – 80 50 – 1350  
(WB-F344 cells)(IV) 
 
DNA strand breaks 1 – 1000(1,2,3,4,5,6) 27.5 – 880(5) 29.6 – 118.4(5) 1010 – 8080(5) 
 
UDS 2 – 56.25(7,8) 1.5 – 6.25(7) 12.8 – 20(7) 100(7) 
 
Mutations 3.45 – 138(9,10,11,12,13,14) 43.7 – 65.6(15) 23.7 – 47.3(16) - 
 
SCEs 0.87 – 276(1,5,13,17) 5.5 – 22(5) 8.9(5) 145 – 441(5) 
 
CAs 2.3 – 368(5,9,13,17,18) 22 – 55(5) 11.8 – 14.8(5) 423 – 1616(5) 
 
MN 50 – 100(7) 6.3 – 25(7) 25(7) 100 – 200(7) 
_________________________________________________________________________________________ 
a)Note: Due to different experimental assays and conditions between the tests, the effective concentrations 
cannot be exactly compared. 
1Brunborg et al., 1991; 2Chang et al., 1991; 3Holme et al., 1999; 4Marsteinstredet et al., 1997a; 5Mäki-
Paakkanen et al., 2001; 6Nunn and Chipman, 1994; 7Le Curieux et al., 1999; 8Nunn et al., 1997; 9Harrington-
Brock et al., 1995; 10Hyttinen et al., 1996; 11Jansson and Hyttinen, 1994; 12Matsumura et al., 1994; 13Mäki-
Paakkanen et al., 1994; 14Woodruff et al., 2001; 15Niittykoski et al., 1995; 16Jansson et al., 1995; 17Jansson et 
al., 1993; 18Meier et al., 1987a. 
   
 
Activation of signal transduction pathways are known to regulate GJIC. The action 
of a number of kinases may affect a wide variety of Cx processes ranging from the 
expression of Cx genes to the degradation of the gap junction channels (Cruciani 
and Mikalsen, 2002; Hervé and Sarrouilhe, 2002). The mechanisms by which TPA, 
a well known potent tumor promoter and a positive control in the current studies, 
inhibits GJIC in rat liver epithelial cells, involve hyperphosphorylation of Cx43 and 
activation of both PKC and MAPK signaling pathways (Lampe et al., 2000; Rivedal 
and Opsahl, 2001; Ruch et al., 2001; Rivedal and Leithe, 2005). Therefore, the role 
of hyperphosphorylation of Cx43 and those of PKC and MAPK signaling pathways 
on the inhibition of GJIC by CHFs were evaluated in WB-F344 cells. 
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Of the post-translational modifications, hyperphosphorylation of Cx is thought to 
represent a major mechanism of aberrant GJIC induction by chemical agents 
(Yamasaki and Naus, 1996). However, sometimes the phosphorylation status of Cx 
can remain unchanged even though GJIC is inhibited (Guan et al., 1995; Sai et al., 
1998; Suzuki et al., 2000). WB-F344 cells contain mainly Cx43 protein (Ruch et al., 
1994). Treatment of the WB-F344 cells with MX did not increase the basal level of 
phosphorylation of Cx43. Thus, the mechanisms responsible for aberrant GJIC 
induced by MX do not seem to involve hyperphosphorylation of Cx43. Instead, it is 
likely that MX affected GJIC by altering the Cx43 expression. The expression of all 
of the isoforms of Cx43 protein were reduced. Complete degradation of the Cx43 
protein was observed at the highest MX concentration. Reduction of the available 
Cx43 protein gradually leads to fewer and fewer gap junctions and to inhibition of 
GJIC. 
With prolonged TPA treatment, GJIC was re-established. Proteosomal degradation 
of PKC is one mechanism to account for this restoration (Leithe et al., 2003). The 
mechanisms for the inhibition of GJIC by MX appear to be different from those of 
TPA. The inhibitory response of MX was independent of the exposure period and 
inhibition of PKC, which means that MX did not inhibit GJIC by activating PKC. 
Instead, the inhibition of GJIC by MX was clearly dependent upon the activation of 
the MAPK signaling pathway. It has been demonstrated that tumors exhibiting 
increased activity of MAPK pathways may progress towards more advanced tumor 
states in the absence of Cx32-mediated GJIC (King and Lampe, 2004). The MAPKs, 
which belong to the ras/raf/MEK/MAPK signaling pathway (Fig.10), regulate 
various cellular activities, such as gene expression, mitosis, differentiation, and cell 
survival/apoptosis (Rodriguez-Viciana et al., 2004). Activation of the 
ras/raf/MEK/MAPK pathway seems to make a pivotal contribution in driving 
growth and progression of tumors in humans (Thompson and Lyons, 2005). The 
members of the ras gene family encode for 21-kDa proteins (p21ras) that are 
localized on the inner surface of the plasma mambrane and have GTP/GDP binding 
capacity (Barbacid, 1987). Ras is active in the GTP-bound form and inactive in the 
GDP-bound form. Mutation of a ras gene converts that gene into the active 
oncogene, which results in the ras protein remaining predominantly bound to GTP 
compared with the wild-type variants. Activated ras stimulates raf activity, which 
then switches on MEK and this in turn activates MAPK (Rodriguez-Viciana et al., 
2004). However, activation of MAPK does not invariably occur via mutations of ras 
genes (Pesse et al., 2005; Zuidervaart et al., 2005). 
ROS have been observed to modulate GJIC (Hu and Cotgreave, 1995; Kojima et al., 
1996; Upham et al., 1997). MAPKs are also known to be activated by oxidative 
stress (Stevenson et al., 1994). MX induced ROS production in murine L929 
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fibrosarcoma cells but only at relatively high concentrations (100 – 1000 µM) (Zeni 
et al., 2004). If high MX concentrations are needed for ROS production in all cells, 
then ROS cannot probably contribute to the MX-induced carcinogenesis. 
The exact site(s) of action of MX remains to be elucidated but these present 
mechanistic studies suggest that nongenotoxic effects may be contributing to the 
carcinogenicity of MX (Fig. 10). 
6.3.2 CMCF 
CMCF was classified as an initiator, but not as a promoter in the two-stage mouse 
fibroblast cell transformation assay  (Laaksonen et al., 2003). It even decreased the 
number of foci induced by MC. Compared to MX, CMCF was a 10,000-fold weaker 
inhibitor of GJIC in Balb/c 3T3 cells and higher concentrations were needed to 
evoke the inhibitory effect on cell communication than to affect the foci formation. 
The low potential of CMCF to inhibit GJIC is compatible with its lack of potency to 
promote foci formation in those cells. However, in WB-F344 cells, CMCF had 
similar effects on gap junctions as MX and it was only a 3.3-fold weaker inhibitor of 
GJIC than MX. Moreover, the concentrations needed to inhibit GJIC in WB-F344 
cells were lower than those required in Balb/c 3T3 cells. This may mean that for 
CMCF the GJIC-inhibiting effect is tissue- or species-specific. CMCF is definitively 
a genotoxic agent in vitro, but the responses related to tumor promotion leave its 
role in tumor promotion as an open question. CMCF has evoked the genotoxic 
effects in mammalian cells in vitro at the similar concentration ranges as it inhibits 
GJIC (Table 8). 
6.3.3 MCA 
MCA was a promoter, but not an initiator, in the two-stage mouse fibroblast cell 
transformation assay (the lowest effective concentration: 5.9 µM) (Laaksonen et al., 
2003). MCA inhibited GJIC in Balb/c 3T3 cells at concentrations below those 
needed for promotion of the foci formation. Thus, the inhibition of the cell-cell 
communication might facilitate the foci formation in the mouse fibroblasts. The 
finding that MCA blocked GJIC also in WB-F344 cells, apparently by the same 
mechanisms as MX, support the concept that MCA could act as a tumor promoter. 
MCA inhibited GJIC at the lower or similar concentrations than those needed to 
cause genotoxicity in mammalian cells in vitro (Table 8). 
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6.3.4 MCF 
MCF acted as both an initiator and a promoter in the two-stage mouse fibroblast cell 
transformation assay (Laaksonen et al., 2003). MCF inhibited GJIC also in Balb/c 
3T3 cells. The concentrations needed to inhibit GJIC were clearly higher than those 
known to be effective in the promotion phase of the transformation assay (the lowest 
effective concentration: 6.7 µM). MCF blocked GJIC also in WB-F344 cells at a 
similar concentration range as in Balb/c 3T3 cells. The concentrations of MCF 
needed to inhibit GJIC were similar as those required to evoke the genotoxic effects 
in mammalian cells in vitro (Table 8). Overall, MCF was the weakest inhibitor of 
GJIC in both cell lines and it possessed only a low potential to inhibit GJIC. Thus, 
other mechanisms seem to be involved in the foci formation caused by MCF. 
Taken together, the current results show that MX inhibits GJIC by altering the 
expression of Cx43 in the cells of one target tissue of its carcinogenicity. Cxs are a 
multigene family. Each cell type has its own characteristic pattern of Cx proteins. 
Cx32 is the major Cx expressed by rat hepatocytes. Instead, cholangiocytes (bile 
duct epithelial cells) express Cx43 as their predominant Cx protein (Neveu et al., 
1995; Bode et al., 2002). Normal rat thyroid follicular cells express Cx43, Cx32, and 
Cx26 (Meda et al., 1993). MX induced especially cholangiomas, epithelial tumors 
of the bile duct, and thyroid follicular tumors in rats (Komulainen et al., 1997). At 
present it is not known whether one type of connexins is more sensitive to MX than 
others and could that explain the carcinogenicity of MX in general or its tissue 
specificity. A specifically altered expression of Cx43 could well explain MX’s 
propensity to evoke cholangiomas. 
6.4 Effects of MX on apoptosis (III) 
Many tumor promoters inhibit both GJIC and apoptosis. A functional GJIC system 
may be necessary for initiation of apoptosis and thus inhibition of GJIC would 
inhibit apoptosis and in that way support tumor promotion (Trosko and Goodman, 
1994). Apoptosis has been observed also in the absence of functional gap junctions 
(Kolaja et al., 2000; Mally and Chipman, 2002) i.e. they are necessarily not always 
interrelated. Gap junctions may serve a regulatory function between cell growth and 
apoptosis (Wilson et al., 2000). 
MX caused apoptosis in Balb/c 3T3 cells but at much higher concentrations and 
after longer incubations than those needed to inhibit GJIC. Apoptosis occurred only 
in a narrow concentration window of 100 – 200 µM. In promyelocytic leukemic HL-
60 cells, a similar window-effect (30 – 100 µM) for MX-induced apoptosis has been 
observed (Marsteinstredet et al., 1997b). The authors suggested that the DNA in 
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cells exposed to 300 µM MX was “arrested” at an early apoptotic stage with altered 
chromatin. It would be interesting to determine whether MX inhibits apoptosis at 
concentrations which do not yet induce apoptosis. Inhibition rather than induction 
would support tumor growth and development. 
6.5 Implications for risk assessment 
Risk assessment of chlorinated drinking water is complicated because of the huge 
numbers and different types of DBPs. There may be also marked interactions 
between DBPs, which should be taken into account in risk assessment. The 
observation that a cancer risk is associated with bacterial mutagenicity of drinking 
water suggests that mutagenic/genotoxic compounds may increase the risk. CHFs 
represent a group whose genotoxicity in mammalian cells has been definitively 
observed in vitro.  
MX was evaluated as possibly carcinogenic to humans by IARC (IARC, 2004). An 
important question is whether MX is a complete carcinogen, a tumor initiator and 
promoter. This consideration would make it a more potent carcinogen than initially 
thought. MX is clearly a genotoxic compound in mammalian cells in vitro (Table 1), 
but there is some inconsistency in its genotoxic potency in vivo (Tables 2a and 2b). 
Both the two-stage cell transformation assay and GJIC studies suggest that MX is 
also a tumor promoter, but this effect in vivo has not been evaluated. The classical 
multistage model of chemical carcinogenesis holds the view that the initial event is a 
genotoxic one, where the chemical carcinogen induces mutations in oncogenes 
and/or tumor suppressor genes and these initiated cells are then promoted by 
nongenotoxic mechanisms turning them into a malignant genotype (Pitot, 1993). An 
alternate model of chemical carcinogenesis suggests that most chemical carcinogens 
work through nongenotoxic mechanisms. In that model, mutations in oncogenes are 
thought to be caused by some independent “spontaneous” event and these 
spontaneously-initiated cells, induced by either errors in repair of endogenous or 
exogenous agents or by errors in replication of normal DNA templates, are then 
promoted by the nongenotoxic action of the chemical, i.e. the chemical is an 
epigenetic agent (Trosko, 1997; Trosko, 2001; Trosko and Upham, 2005). In both 
models, MX could be a carcinogen, but tumor promoters are more likely have 
threshold level of action, i.e. they need higher concentrations for their action 
compared to genotoxic compounds. Exposure to tumor promoters must also be 
regular and sustained (which is the case for drinking water by-products), otherwise 
the process of promotion can be interrupted (Trosko and Upham, 2005). 
The carcinogenicity of CHFs other than MX is still unexplored, but these 
compounds are genotoxic in mammalian cells. The present studies revealed that in 
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rat liver epithelial cells, the potencies of CMCF and MCA to inhibit GJIC were not 
much lower than the potency of MX. Thus, the other CHFs cannot be excluded from 
any risk assessment. However, more information about their in vivo effects are 
needed before their contribution to the risks associated with drinking chlorinated 
water can be assessed. 
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7 CONCLUSIONS 
1. In the MX-induced rat liver tumors, no mutations in Ki-, Ha-, and N-ras 
oncogenes and only four mutations in the p53 tumor suppressor gene were 
detected. These results point to the presence of alternative molecular 
pathways that do not involve point mutations in ras genes and p53 gene. 
2. MX-induced rat hepatocellular adenomas and carcinomas did not express 
p53 protein, which is in good agreement with the mutation data. Instead, all 
the cholangiomas and cholangiocarcinomas overexpressed p53 protein, but 
this was proposed to be associated with the age of the rats. p53 and p21 Ki-
ras proteins were not expressed abnormally in rat thyroid tumors. Thus, 
these immunohistochemical findings support the concept that mutations in 
Ki-ras and p53 genes are not targets in the MX-induced tumorigenesis. 
3. CHFs inhibited GJIC in Balb/c 3T3 mouse fibroblast cells and in WB-F344 
rat liver epithelial cells, the target cells of MX tumorigenicity. MX was the 
most potent inhibitor of GJIC in both cell lines. Considering the effective 
concentrations of each CHF in Balb/c 3T3 cells, the inhibition of GJIC may 
be one mechanism through which MX and MCA are involved in the 
promotion of malignant foci formation in mouse fibroblasts. In WB-F344 
cells, CHFs inhibited GJIC through the activation of MAPK signaling 
pathway and by altering Cx43 expression. The inhibition of GJIC by MX 
may have relevance as a nongenotoxic mechanism involved in MX-induced 
carcinogenesis. 
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